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ABSTRACT 
 
Milk proteins which make up 3.5% of the bovine milk are classified into casein and whey proteins. A 
high intake of milk proteins, especially whey proteins, has been shown to exert the beneficial effects 
on obesity and obesity related diseases in both humans and animals via unknown mechanisms. The 
aim of the present study was to investigate the potential of different whey proteins, i.e. whey protein 
isolate (WPI), alpha-lactalbumin (α-lac), lactoferrin (LF) and microfiltered native whey (MFNW), and 
their mechanisms of actions to prevent and treat diet-induced obesity and its consequences in 
C57Bl/6J mice.  
    In the present study, all of the tested whey proteins were given as the only protein source in high-fat 
diets with a constant protein (18 % of the energy): carbohydrate (21 % of the energy): fat (61 % of the 
energy) ratio. We used weekly body weight measurements, daily food intake monitoring, apparent fat 
digestibility, dual-energy X-ray absorptiometry, oral glucose tolerance test, monitoring of fat pad 
weights, as well as biochemical measurements in order to assess the metabolic effects of whey 
proteins. 
    Compared to casein, WPI (rich in lactoperoxidase, LF, growth factors and immunoglobulins) and 
LF accelerated weight and fat loss under energy restriction, and inhibited weight and fat regain during 
the ad libitum feeding after energy restriction without interfering with energy intake or apparent fat 
digestibility in C57Bl/6J mice. Both WPI and LF ameliorated fatty liver formation, and exerted 
beneficial effects on glucose tolerance under high-fat-feeding. The beneficial effects of WPI occurred 
in a dose-dependent manner. In addition, LF reduced the adipose tissue inflammation after weight 
regain, a property not shared with WPI. The further biochemical analysis indicated that these effects 
of both WPI and LF are mediated, at least partly, via the inhibition of mTOR nutrient sensing pathway 
and the activation of SIRT3 in the liver. Alpha-lac has been reported as one of the most effective whey 
protein fractions for accelerating weight and fat loss during energy restriction in the same mouse 
model. It was observed that the effects of α-lac on body weight and fat under energy restriction could 
be reproduced by supplying an amino acid mixture with an identical amino acid profile, which 
indicates that the anti-obesity effects of α-lac were mainly mediated by its individual amino acid 
composition. The MFNW produced by polymeric membranes using novel microfiltration technology, 
prevented weight gain and fat accumulation without interfering with energy intake or glucose 
homeostasis during ad libitum high-fat-feeding. The findings also suggest that the beneficial effects of 
MFNW are largely due to its rich α-lac content.  
    In summary, the intake of whey proteins exerts anti-obesity effects in C57Bl/6J mice during high-
fat-feeding. WPI and LF enhance weight loss, prevent weight regain and ameliorate obesity induced 
fatty liver formation. The anti-obesity effects of WPI are attributable, to a large extent, to its LF 
content. The anti-obesity effects of α-lac are mainly due to its amino acid composition. The observed 
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beneficial effects of MFNW point to a possible method to generate whey proteins with high bioactive 
value on a large scale. 
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1 Introduction 
 
The worldwide prevalence of obesity, a condition that substantially elevates the risk of morbidity 
from hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, gallbladder disease, 
osteoarthritis, sleep apnea and respiratory problems, as well as endometrial, breast, prostate, and colon 
cancers, poses a major public health challenge (National Institutes of Health, 1998). Obesity is also 
strongly associated with a chronic low-grade inflammation and a state of insulin resistance, which is a 
primarily result of the non-alcoholic fatty liver disease (NAFLD) (Angulo, 2007; Guillet et al., 2012). 
Weight loss via life style modification, i.e. the combination of dietary therapy, physical activity and 
behavioral therapy, is the mainstay of treatments for obesity (National Institutes of Health, 1998). 
Nutrition therefore plays a crucial role in the prevention and treatment of obesity and its consequences.  
    Epidemiological studies have shown that the intake of dairy products is related to reduced body 
mass index (BMI) (Mirmiran et al., 2005; Marques-Vidal et al., 2006; Varenna et al., 2007), and the 
risk of type 2 diabetes and metabolic syndrome (Crichton et al., 2011). Dietary calcium has been 
proposed to play a role in the effect of dairy products on body weight by increasing fat excretion 
(Christensen et al., 2009) and 1,25-dihydroxy-vitamin D3-mediated alterations in adipocyte 
metabolism (Zemel, 2000; Shi et al., 2001b, 2002; Zemel & Miller, 2004). In addition, dairy proteins, 
especially whey proteins, have been postulated to account at least in part for the anti-obesity effect of 
dairy products (Zemel, 2005; Pilvi et al., 2007, 2009; Frestedt et al., 2008; Royle et al., 2008).  
    Normally, whey proteins are acquired by the ultrafiltration of whey produced during cheese making 
(Heino et al., 2007). However, the additives used in the manufacture of cheese may impair the 
functional properties and decrease the nutritional value of whey proteins. Microfiltration has been 
suggested as an excellent technique to remove the native whey from milk in order to enhance the 
quality of whey proteins (Brans et al., 2004). It has been reported that the MFNW exerts superior 
functional properties as compared with cheese whey protein (Heino et al., 2007). 
    The present study aimed to investigate the potential effects of different whey protein fractions and 
their mechanisms of actions in the prevention and treatment of diet-induced obesity and its 
consequences in an experimental model of diet-induced obesity. 
 
11 
 
2 Review of the literature 
 
2.1 Obesity 
 
2.1.1 Obesity and its classification 
 
Obesity has been described as a chronic condition characterized by abnormal or excessive body fat 
accumulation (Gortmaker et al., 2011). The prevalence of obesity has markedly increased since the 
1970s in the United States (Flegal et al., 1998). In the United States, the National Health and Nutrition 
Examination Survey (NHANES) revealed that the obesity prevalence in adults was 33.8% in 2007-
2008, a number which had more than doubled as compared to that in 1976-1980 (Flegal et al., 1998, 
2010). According to the World Health Organization (WHO), 2.8 million people die each year because 
they are overweight or obese (WHO, 2012). In global terms, the prevalence of obesity almost doubled 
between the years 1980 to 2008 (WHO, 2012). 
    There are various measures of obesity, among which body mass index (BMI) is most commonly 
used (Luke et al., 1997; National Institutes of Health, 1998). BMI is defined as a person’s weight (in 
kilograms) divided by the square of his or her height (in meters) (National Institutes of Health, 1998). 
Since BMI is the same for both genders and all ages of adults and significantly correlated with total 
body fat content, it provides the most useful population-level measure of overweight and obesity 
(Revicki & Israel, 1986; National Institutes of Health, 1998). The WHO defines a BMI greater than or 
equal to 25.0 kg/m
2
 as overweight; a BMI greater than or equal to 30.0 kg/m
2
 as obesity (National 
Institutes of Health, 1998). There are three grades of obesity, which are defined according to the 
different BMI levels (Table 1) (National Institutes of Health, 1998). 
 
Table 1 Obesity grades. 
 
Obesity grades BMI (kg/m
2
) 
Grade I 30≤BMI<35 
Grade II 35≤BMI<40 
Grade III BMI≥40 
 
 
2.1.2 The consequences of obesity 
 
Obesity has been found to reduce average life expectancy; its major consequences are cardiovascular 
disease, type 2 diabetes, and the development of several cancers (Fig. 1) (Haslam & James, 2005). It 
substantially increases the risk of morbidity from gallbladder disease, osteoarthritis, sleep apnea and 
respiratory problems, hypertension, stroke, and non-alcoholic fatty liver disease (Fig. 1) (National 
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Institutes of Health, 1998; Haslam & James, 2005). Obesity is also associated with psychological and 
reproductive disorders (Fig. 1) (National Institutes of Health, 1998). In particular, visceral obesity, 
which is an excess intra-abdominal adipose tissue accumulation, is closely linked with diabetes 
mellitus, cardiovascular disease especially hypertension, and some cancers (Tchernof & Despres, 
2013). 
 
 
Fig. 1 The consequences of obesity. 
 
    As long ago as the 1970s, Sims and the colleagues (1973) observed that there were reversible 
increases in fasting concentration of glucose, insulin, triglycerides and impaired glucose tolerance in 
young men without a family history of diabetes, with a BMI of 28.0 kg/m
2
 due to six months 
overfeeding. Weight gain has been reported to associate with enhanced insulin resistance (Swinburn 
et al., 1991) and glucose intolerance (Berger et al., 1975), which are the key factors in the 
development of diabetes. Approximately 90 % of patients with type 2 diabetes have BMI higher than 
23.0 kg/m
2
 (Stevens et al., 2001), and the risk of diabetes markedly increases if there has been early 
weight gain (Wannamethee & Shaper, 1999).  
    Non-alcoholic fatty liver disease is a disease spectrum including hepatic steatosis (non-alcoholic 
fatty liver, (NAFL)), non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis (Adams et al., 2005; 
Bjornsson & Angulo, 2007; Chiang et al., 2011). It refers to excessive fat accumulation, which is 
stored as triglycerides, in hepatocytes such that it exceeds 5 % of the liver weight (Angulo, 2007). 
NAFLD is closely linked to obesity (Marchesini et al., 1999), which is considered as one of the 
aetiological factors for NAFLD (Haslam & James, 2005). It has been proposed that in obese subjects, 
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the increased adiposity and insulin resistance contribute to the progression from NASH to fibrosis via 
the development of a profibrotic environment in liver (Chiang et al., 2011). In the general population, 
the prevalence of NAFLD has been reported as being between 10 - 24 % in different countries, but it 
is present in the majority (57.5 - 74 %) of obese people (Tarantino et al., 2007). NAFLD may even be 
detected in children: the overall incidence is 2.6 %, increasing up to 22.5 - 58.5 % in obese children 
(Tarantino et al., 2007). 
 
2.1.3 The treatment of obesity 
 
An energy imbalance resulting from a combination of an excessive energy intake and a lack of 
physical activity is considered to be the fundamental cause of overweight and obesity, although there 
are a limited number of cases which are due primarily to genetics, medical reasons, and psychiatric 
illness (National Institutes of Health, 1998; Bleich et al., 2008). Therefore, dietary and physical 
activity patterns play a pivotal role in the development of obesity. Life-style therapy, i.e. the 
combination of dietary therapy, physical activity and behavioral therapy, is the recommended 
treatment for obesity (National Institutes of Health, 1998). Pharmacotherapy and surgery are only 
considered as referral treatments for severe and resistant obesity (National Institutes of Health, 1998). 
At the individual level, by limiting energy intake from total fats, increasing consumption of fruit, 
vegetables, legumes, whole grains and nuts, limiting the sugar intake, and enhancing the amount of 
regular physical activity, individuals can achieve energy balance and this will prevent them from 
becoming overweight and obese (WHO, 2012). In the food industry, nutritional approaches are 
attracting more and more attention as valuable ways of enhancing the health-promoting quality of 
food in order to prevent the growing global epidemic of obesity. 
 
2.2 Whey proteins 
 
Bovine milk contains about 3.5 % proteins (Yalcin, 2006). These milk proteins are divided into casein 
and whey proteins; these separate when the pH of milk is lowered to 4.6 (Yalcin, 2006). Casein 
proteins are the phosphoproteins which precipitate from raw skimmed milk with acidification to pH 
4.6 at 20 °C (Farrell et al., 2004). The proteins which remain in the supernatant of milk after 
precipitation of casein are defined as whey proteins (Yalcin, 2006). According to the homology of the 
amino acid sequences, the casein fractions can be further divided into α-s1- and α-s2-caseins, β-casein 
and κ-casein (Yalcin, 2006). Casein proteins are postulated to have various physiological functions, 
such as antibacterial, immunomodulatory, properties as well as enhancing the bioavailability of 
certain minerals (for reviews, see Vegarud et al., 2000; Bouhallab & Bougle, 2004; Meisel, 2005). In 
bovine milk, the average whey to casein ratio is 20: 80 (Yalcin, 2006). Although the amount of whey 
proteins in bovine milk is less than the amount of casein, the inexpensive source and high nutritional 
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quality of whey proteins have encouraged extensive investigation into its functional effects in humans 
(described in detail later).   
 
2.2.1 Whey proteins and its components 
 
Traditionally, whey is considered as a by-product of the cheese-making process (Krissansen, 2007). It 
is the fluid that remains after milk has been curdled and strained to remove the caseins. Whey 
includes proteins, lactose, vitamins, minerals, and traces of fat. Whey proteins consist of five different 
major proteins, including β-lactoglobulin, α-lactalbumin, glycomacropeptide (GMP) (depending on 
the manufacturing methods), proteose peptone 3, immunoglobulins, and bovine serum albumin 
(Krissansen, 2007). In addition, whey proteins contain lactoferrin (LF), lactoperoxidase, natural 
growth factor, and other minor proteins (Krissansen, 2007). It has been claimed that whey proteins 
can exert many different biological activities. These range from effects on bone (Takada et al., 1997; 
Aoe et al., 2001; Yamamura et al., 2002), muscle (Buckley et al., 2010; Pennings et al., 2011; Kanda 
et al., 2013), blood (Pins & Keenan, 2006; Petersen et al., 2009; Pal & Ellis, 2010b; Aldrich et al., 
2011),  immune system (Otani et al., 1995; Kayser & Meisel, 1996; Monnai M, 1997; Wong et al., 
1997b; Ward et al., 2002; Legrand et al., 2005), cancer (Wang et al., 2000; Sternhagen & Allen, 2001; 
Varadhachary et al., 2004; Parodi, 2007), satiety (Bowen et al., 2006a, 2007; Diepvens et al., 2008), 
combatting infections (Brody, 2000; Campagna et al., 2004; Weinberg, 2007; Jenssen & Hancock, 
2009), lipid metabolism (Moreno-Navarrete et al., 2009; Fernandez-Real et al., 2010; Ono et al., 
2010), wound healing (Rayner et al., 2000), mood control (Markus et al., 2002; Orosco et al., 2004) 
and oxidative stress (Bouthegourd et al., 2002; Kent & Bomser, 2003). Whey proteins are also present 
as ingredients in different forms of pharmaceuticals, nutraceuticals and cosmeceuticals (for reviews, 
see Marshall, 2004; Yalcin, 2006; Krissansen, 2007). Due to the wide spectrum of bioactive effects of 
whey proteins and the current advances in processing technologies including ultrafiltration, 
microfiltration, reverse osmosis, and ion-exchange, whey proteins have been incorporated into various 
commercialized products (Table 2) such as dietary protein supplements (Marshall, 2004). The whey 
proteins of special therapeutic importance are α-lactalbumin, β-lactoglobulin, bovine serum albumin, 
immunoglobulins, lactoferrin and lactoperoxidase (Table 3). 
 
 
 
 
 
 
 
 
15 
 
Table 2 Commercialized whey proteins. 
a
 
 
Products Protein concentration Lactose, fat and mineral content 
 
Whey protein isolate 
 
90 - 95 % 
 
Little if any 
 
Whey protein 
concentrate 
 
25 -89 %  
Most commonly available as 80 % 
 
Some lactose, fat and minerals  
When protein concentration increases, fat, 
lactose, and mineral content decreases. 
 
Hydrolyzed whey 
protein 
Variable  
Hydrolysis used to cleave peptide 
bonds 
Larger proteins become smaller 
peptide fractions  
Reduces allergic potential 
compared to non-hydrolyzed 
 
Varies with protein concentration 
Undenatured whey 
concentrate 
Variable  
Usually ranges from 25 - 89 % 
Some lactose, fat and minerals  
When protein concentration increases, fat, 
lactose, and mineral content decreases.  
Processed for preserving native protein 
structures; typically have higher amounts of 
immunoglobulins and lactoferrin 
 
a
 Modified from Marshall, 2004. 
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Table 3 Whey protein components. 
a
 
 
Whey protein components 
Approximate 
percentage 
contributions of the 
major proteins in whey 
(%) 
Molecular 
weight 
(kDa) 
Benefits and biological activities 
 
Beta-lactoglobulin  
 
50-55 
 
18.4 
 
Source of essential and branched chain amino acids; Retinal carrier; Binding of fatty acids; 
Antioxidant 
 
Alpha-lactalbumin 20-25 14 Source of essential and branched chain amino acids; Ca carrier; Immunomodulation; 
Anticarcinogenic; Antiulcer; Health effects on mood; Anti-inflammatory 
 
Glycomacropeptide 10-15   Source of branched chain amino acids; Lacks the aromatic amino acids phenylalanine, 
tryptophan, and tyrosine; Inhibitory effect on acid gastric secretions; Immunomodulation; 
Antiviral 
 
Proteose Peptone 3 12   Enhances monoclonal antibody production; Antibacterial 
 
Immunoglobulins 10-15   Immune protection 
 
Bovine Serum Albumin 5-15 66.5 Source of essential amino acids; Anti-cancer activity in some cell lines; Opioid agonist 
activity; Food intake regulation 
 
Lactoferrin 1 80 Antioxidant; Antimicrobial, wound healing; Antiviral; Promoting growth of beneficial 
bacterial; Anticarcinogenic; Antitoxin; Anti-inflammatory; Antithrombotic; Fe absorption; 
Immunomodulation 
 
Lactoperoxidase 0.25-0.5   Antimicrobial, wound healing 
 
Natural growth factor     Wound healing 
 
a
 Modified from Marshall, 2004; Yalcin, 2006; Krissansen, 2007.
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Beta-lactoglobulin  
 
Beta-lactoglobulin, a member of the lipocalin family, is the most abundant protein in bovine milk, 
accounting for approximately half of the total proteins in bovine whey, while it is absent in human 
milk (Perez and Calvo, 1995; Sawyer & Kontopidis, 2000; Kontopidis et al., 2004; Marshall, 2004; 
Krissansen, 2007). It is a noncovalently linked dimer containing two internal disulfide bonds and one 
free thiol group (Kontopidis et al., 2004; Yalcin, 2006). Primarily, β-lactoglobulin serves as a source 
of essential and branched chain amino acids (Marshall, 2004). In addition, it has binding sites for 
calcium, zinc, minerals, fat-soluble vitamins and it displays partial sequence homology to retinol 
binding proteins (Perez and Calvo, 1995; Kontopidis et al., 2004; Yalcin, 2006; Krissansen, 2007). 
Beta-lactoglobulin has been reported to bind retinol, triglycerides and long-chain fatty acids in order 
to enhance their intestinal uptake in preruminant calves (Perez & Calvo, 1995; Kushibiki et al., 2001), 
and it is also a major allergen in bovine milk and thus is responsible for milk allergy (Krissansen, 
2007; Tsabouri et al., 2014). 
 
 
Alpha-lactalbumin 
 
Alpha-lactalbumin, which is found in both human and bovine milk, accounts for roughly 20-25 % of 
whey proteins (Lonnerdal & Lien, 2003; Marshall, 2004). It is a single-chain polypeptide of 123 
amino acids with a molecular mass of approximately 14 kDa (Brew & Grobler, 1992). It is recognized 
as a part of the lactose synthase complex and it is a rich source of amino acids, especially in infant 
nutrition, due to the wide spectrum of its amino acids composition which allows it to a large extent to 
meet the essential amino acid requirements of newborn infants (Lonnerdal & Lien, 2003). Alpha-
lactalbumin is a calcium binding protein which enhances the absorption of calcium (Lonnerdal & 
Glazier, 1985; Yalcin, 2006). Several in vitro and in vivo studies have indicated that α-lactalbumin 
can exert a variety of physiological functions from immune-stimulating (Gattegno et al., 1988; Jaziri 
et al., 1992; Migliore-Samour et al., 1992; Kayser & Meisel, 1996; Wong et al., 1997b), antiulcer 
(Matsumoto et al., 2001), anti-inflammatory (Yamaguchi et al., 2009) to anticancer activity 
(Sternhagen & Allen, 2001) and it may even have a beneficial effect on mood (Markus et al., 2002; 
Orosco et al., 2004). 
 
Glycomacropeptide 
 
Glycomacropeptide (GMP) is a protein accounting for 10-15 percent of whey (Saito et al., 1991; 
Marshall, 2004). It originates from the action of chymosin on casein in the cheese-making process 
(Eigel et al., 1984; van Hooydonk et al., 1984). Thus, GMP is only present when chymosin is used in 
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the processing (therefore cottage cheese which is not made with chymosin does not produce GMP). 
GMP is rich in branched chain amino acids, but lacks the aromatic amino acids such as phenylalanine, 
tryptophan, and tyrosine (Brody, 2000; Krissansen, 2007). It has been reported to inhibit the secretion 
of acid gastric and modifies the blood concentration of regulatory digestive peptides (Yvon et al., 
1994). GMP has also been claimed to possess immunosuppressive (Otani et al., 1995), 
immunostimulatory (Monnai M, 1997), and anti-infective (Brody, 2000) properties. 
 
Proteose Peptone 3 
 
The proteose peptones are the proteins remaining in solution after milk has been heated at 95°C for 20 
mins and then acidified to pH 4.7 (Rowland, 1937, 1938). These consist of four major components, of 
which the proteose-peptone component 3 (PP3) fragment represents 25% by weight (Sorensen & 
Petersen, 1993). PP3 is absent in humans, and only found in whey which is produced by the 
fermentation of fat-free bovine milk. PP3 has been reported to enhance monoclonal antibody 
production by human hybridoma cells (Sugahara et al., 2005) and it has the potential to inhibit the 
growth of both gram positive and negative bacteria (Campagna et al., 2004). 
 
Immunoglobulins 
 
Immunoglobulins (Ig) are antibodies or gamma-globulins, which contain five classes of antibodies i.e. 
IgA, IgD, IgE, IgG, and IgM (Woof & Burton, 2004). In whey, immunoglobulins represent 10-15 
percent of the total proteins (Marshall, 2004). Not do they only provide passive immunity for the 
neonate, but they also may potentially be powerful agents which could be incorporated in diets to 
remove toxic and undesirable dietary factors (Krissansen, 2007). Furthermore, the hyperimmune 
whey from milk, which is acquired by immunizing cows with a pathogen or its antigens, can 
potentially provide prophylactic protection against many different infectious gut microbes such as 
rotavirus and Helicobacter pylori (Korhonen et al., 2000). 
 
Bovine Serum Albumin 
 
Bovine serum albumin is a large protein which accounts for approximately 5-15 percent of total whey 
protein (Marshall, 2004; Krissansen, 2007). In addition to being a source of essential amino acids, its 
potential therapeutical activity is largely unexplored. It has displayed anti-cancer activity in a cell line 
(Laursen I, 1990). In addition, some BSA-derived peptides have been reported to exert opioid agonist 
activity (Meisel, 2005) and are maybe involved in the regulation of food intake (Ohinata et al., 2002). 
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Lactoferrin 
 
Lactoferrin is a single-chain iron-binding glycoprotein of mammary origin which can be found in the 
milk of most species (Lonnerdal & Iyer, 1995). It is an 80-kDa protein with a globular protein folded 
into two highly homologous iron-binding lobes (Metz-Boutigue et al, 1984; Anderson et al., 1987, 
1989). In adults, LF is generated by glandular epithelial cells and secreted into mucosal fluids (Ward 
et al., 2005). LF is highly detected in colostrum and milk (Masson et al., 1966; Levay & Viljoen, 
1995). It is also found with lower levels in tears, nasal fluids, saliva, pancreatic, gastrointestinal and 
reproductive tissue secretions (Masson et al., 1966; Levay & Viljoen, 1995). LF is the most abundant 
protein of all of the hundreds of low-abundance whey proteins (about 1%) (Krissansen, 2007). The 
evidence is accumulating that LF affects iron homeostasis, cellular growth and differentiation, and 
exerts anti-bacterial, anti-viral, anti-inflammatory and anti-cancer properties (for reviews, see Levay 
& Viljoen, 1995; Brock, 2002; Ward et al., 2002; Legrand et al., 2005; Weinberg, 2007; Gonzalez-
Chavez et al., 2009; Jenssen & Hancock, 2009). In addition, LF has recently been reported to exert a 
regulatory effect on lipid metabolism in humans (Moreno-Navarrete et al., 2009; Fernandez-Real et 
al., 2010; Ono et al., 2010). It has been postulated that one of potential mechanism to explain the 
observed biological functions of LF is the ability of LF to modulate cellular signaling pathways after 
binding to a wide range of epithelial and immune cells (Ward et al., 2005).  
 
Lactoperoxidase 
 
Lactoperoxidase is the most abundant enzyme in whey protein fractions; it ends up in whey after the 
curding process (Marshall, 2004). It represents a mere 0.25-0.5 percent of total protein in whey 
(Marshall, 2004). Lactoperoxidase has been reported to be able to catalyze the peroxidation of 
thiocyanate and some halides (such as iodine and bromium), which eventually produce products that 
inhibit growth and even kill bacterial species (Kussendrager & van Hooijdonk, 2000). Oral 
administration of lactoperoxidase has shown to be able to attenuate pneumonia in mice with influenza 
virus infection by inhibiting the infiltration of inflammatory cells into the lung (Shin et al., 2005). The 
treatment of sheep neutrophils with lactoperoxidase revealed a dose-dependent enhancement of 
superoxide production (Wong et al., 1997a). 
 
Natural growth factor 
 
Whey contains proteins which exert a dramatic impact on cell growth; they promote the synthesis of 
DNA and protein and inhibit the degradation of protein in a series of mammalian cell lines in culture 
(Smithers et al., 1996). These growth factors can be acquired from cheese whey if it is prepared by 
membrane and chromatographic techniques (Ballard, 1991). Several growth factor activities including 
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insulin-like growth factor (IGF)-I, IGF-II, platelet-derived growth factor (PDGF), transforming 
growth factor, acidic and basic fibroblast growth factors have been detected in whey extract (Francis 
et al., 1995; Rogers et al., 1995; Rogers, 1995). These growth factors have been observed to reverse 
the healing deficit associated with diabetes (Greenhalgh et al., 1990), cytotoxic therapy (Lawrence et 
al., 1986), administration of steroids (Pierce et al., 1989), radiation (Mustoe et al., 1989; Cromack et 
al., 1993), and ischemia (Uhl et al., 1993). 
 
2.2.2 The digestion and absorption of whey proteins 
 
After their oral intake and processing, whey proteins are hydrolyzed by an array of proteases and 
peptidases which are secreted from the stomach, pancreas or bound to the brush border membrane of 
enterocytes (Daniel, 2004). These enzymatic degradation generates a number of short- and medium-
sized peptides as well as free amino acids (Daniel, 2004). Most of the peptides formed after 
hydrolysis are rapidly and ultimately degraded into amino acids, which are taken up into the blood 
circulation from the small intestine, whereas certain whey proteins and their derived peptides are more 
resistant to hydrolysis. For instance, both α-lactalbumin and β-lactoglobulin are partly resistant to the 
digestion with human gastric and duodenal juice in vitro (Almaas et al., 2006). Furthermore, 
lactoferrin has been demonstrated to be absorbed intact in mice (Fischer et al., 2007). Whey proteins 
derived peptides have been postulated to exert a variety of physiological functions; these have been 
reported to range from opioid agonist and antagonist effects to ACE-inhibitory and antimicrobial 
effects (for review, see Meisel, 2005). However, due to the complexity of protein digestion in vivo, a 
detailed characterization of the components formed after digestion of whey proteins needs to be 
conducted in order to explore the role of bioactive peptides in the beneficial effects of their precursor 
proteins. 
    Amino acids are organic substances which contain both amino and acid groups (Wu, 2009). They 
are primarily considered to serve as building blocks of proteins and polypeptides. There is growing 
evidence to suggest that there are some amino acids which can regulate key metabolic pathways that 
are necessary for maintenance, growth, reproduction and immunity in organisms (Wu et al., 2007a, b, 
c; Suenaga et al., 2008). These amino acids are defined as functional amino acids and they include 
arginine, cysteine, glutamine, leucine, proline and tryptophan (Wu, 2009). According to the key 
regulatory roles of functional amino acids in nutrition and metabolism (for review, see Wu, 2009), 
dietary supplementation with the functional amino acids may be beneficial for ameliorating certain 
health problems (e.g. neonatal morbidity and mortality, fetal growth restriction, weaning-associated 
intestinal dysfunction and wasting syndrome, cardiovascular disease, obesity, diabetes, metabolic 
syndrome, and infertility) and maximizing the efficiency of metabolic transformation to improve 
health in both humans and animals.  
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2.3 Health effects of whey proteins 
 
2.3.1 Obesity and whey proteins 
 
2.3.1.1 Clinical studies 
 
Based on a search in the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) data-base for randomized 
controlled trials concerning whey proteins, it was found that the studies had focused on growth and 
allergy of infants, body weight, body composition, muscle hypertrophy, protein synthesis, 
gastrointestinal function, blood pressure, insulin responses, appetite, satiety, thermogenesis, and bone 
health. Those trials which had been designed to investigate the health effects of whey proteins in 
overweight/obese subjects are described in Table 4.  
The effects of whey protein intake have been tested under different conditions including free-living 
style, energy restriction (ER), and energy restriction (weight loss) followed by ad libitum energy 
intake (weight regain). In a 12-month study, GMP-enriched whey protein isolate showed effects on 
overall sustained weight loss (10 kg) in both obese men and women (Keogh & Clifton, 2008). The 
consumption of whey supplement achieved a significant reduction in body weight in overweight 
women, while no difference was observed while consuming a fortified collagen hydrolysate protein 
supplement (Hays et al., 2009). Free-living overweight or obese individuals consuming a daily 
supplementation of whey proteins (56 g protein/day) had a decrease in body weight and fat mass after 
23 weeks (Baer et al., 2011). During the caloric restriction-induced weight loss, the supplementation 
of whey proteins with an essential amino acids formulation promoted the loss of adipose tissue in 
elderly, obese individuals (Coker et al., 2012). In a weight loss followed by weight regain study, 
although an elevated intake of whey protein achieved similar effects on weight and fat loss as 
compared with mixed proteins, significantly improved regional fat loss was observed in whey protein 
group (Aldrich et al., 2011). Furthermore, Mojtahedi and colleagues (2011) observed that a higher 
whey protein intake during weight loss could maintain muscle relative to body weight lost in 
overweight and obese women. However, in a study comparing the effects of casein and whey proteins 
in obese subjects, the intake of whey proteins was unable to change either the body weight or the body 
composition as compared with casein after 12 weeks supplementation (Pal et al., 2010a). Interestingly, 
when combined with resistance exercise, the supplementation of casein proteins achieved greater 
mean fat loss and a significant strength increase as compared with whey proteins in overweight police 
officers (Demling & DeSanti, 2000). In addition to the effects on body weight and body composition, 
the intake of whey proteins also exerted beneficial effects on the consequences and other indicating 
parameters of obesity including blood pressure, blood glucose, insulin level, triglyceride 
concentration and satiety (Table 4) (Bowen et al., 2006a, 2006b, 2007; Pins & Keenan, 2006; 
Diepvens et al., 2008; Petersen et al., 2009; Pal et al., 2010a, b; Pal & Ellis, 2010b; Aldrich et al., 
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2011; Baer et al., 2011; Berthold et al., 2011; Holmer-Jensen et al., 2011, 2012, 2013; Gouni-Berthold 
et al., 2012; Lorenzen et al., 2012; Sheikholeslami Vatani & Ahmadi Kani Golzar, 2012). However, 
controversial evidence exists (Claessens et al., 2009; Keogh et al., 2010; Pal & Ellis, 2011; Ang et al, 
2012; Arnberg et al., 2012; Weinheimer et al., 2012; Arnarson et al., 2013).  
 
2.3.1.2 Preclinical studies 
 
Whey protein intake has had beneficial effects on obesity and obesity related consequences in animal 
models. In one study concerning the effects of dietary whey proteins in rats, whey protein diet 
inhibited body weight and fat gain after ten weeks’ feeding period as compared with control diet 
(Zhou et al., 2011). Interestingly, the whey protein fed rats showed decreased food intake and 
increased fat oxidation, which might contribute to the effects of whey proteins on fat gain. As 
compared with red meat, a high-whey-protein diet reduced body weight gain, energy intake, adiposity 
and increased insulin sensitivity in Wistar rats (Belobrajdic et al., 2004). Royle et al. (2008) reported 
that whey protein isolate combined with GMP decreased body weight gain and body fat accumulation 
in Wistar rats without interfering with the food intake, and furthermore the whey protein isolate alone 
appeared to have the major influence accounting for 70% of the overall effect on body weight gain. 
Shertzer et al. (2011) observed that whey protein isolate inhibited body weight and fat gain, increased 
lean body mass, but did not change energy consumption in mice fed a high fat diet. There is a report 
that a whey protein diet could effectively suppress body weight and fat gain as compared with a 
casein diet in combination with calcium supplementation in mice receiving ad libitum high-fat diet 
feeding (Pilvi et al., 2007). However, under low-fat (fat containing 11.8 % of the energy in the diets) 
feeding, neither the high whey proteins nor a corresponding leucine supplementation significantly 
affected body weight gain or body composition in mice (Noatsch et al., 2011). Interestingly, it has 
been reported that the complete dairy protein showed better effects against body weight gain than 
whey or casein alone in obese rats (Eller & Reimer, 2009). 
    Beta-lactoglobulin enriched high protein diet reduced body weight and the adiposity index in obese 
rats as compared with whey and milk proteins (Pichon et al., 2008). Both consumption of β-
lactoglobulin and whey proteins reduced energy intake, body weight and adiposity in rats fed with 
high-protein high-fat diet as compared with milk proteins (Pichon et al., 2008). In an obese mouse 
model, β-lactoglobulin also modestly enhanced the body weight and fat loss under energy restriction 
(Pilvi et al., 2009). Interestingly, Pilvi et al. (2009) showed that α-lactalbumin effectively improved 
the outcomes of weight loss and weight regain in mice fed with a high-fat diet as compared with whey 
protein isolate. In the same study, LF also significantly accelerated both body weight and fat loss 
during energy restriction as compared to the consumption of whey protein isolate (Pilvi et al., 2009). 
  
23 
 
Table 4 Clinical studies on whey proteins and overweight/obesity. 
a
 
 
Patient groups 
Study 
design 
Time 
range 
Intervention 
Main results References 
Control Treatment 
 
38 overweight 
police officers 
 
randomized 
controlled, 
prospective  
 
12 weeks 
 
nonlipogenic, 
hypocaloric diet 
 
1) control diet + RE + casein 
protein hydrolysate 1.5 
g/kg/day; 2) control diet + 
RE + whey protein 
hydrolysate 1.5 g/kg/day 
 
 
Casein group exerted greater mean fat loss and significant 
strength increase. 
 
Demling & 
DeSanti, 
2000 
72 men with a 
BMI range 20.6 - 
39.9 kg/m
2 
(range) 
randomized 
controlled, 
cross-over 
pre-loads 
before 
meal 
  Liquid preloads (1.1 MJ, 450 
ml) containing 50 g items as 
follows: 1) whey; 2) soy; 3) 
gluten; 4) glucose. 
Whey, soy, and gluten inhibited EI in both lean and 
overweight men in comparison with glucose.  Both fasting 
and postprandial GLP-1 concentrations were higher in 
overweight subjects than in lean ones. 
 
Bowen et al., 
2006a 
19 overweight 
men 
randomized 
controlled, 
cross-over 
pre-loads 
before 
meal 
  Liquid preloads (1 MJ) 
containing: 1) whey (55 g); 
2) casein (55 g); 3) lactose 
(56 g); 4) glucose (56 g).  
Acute appetite and EI were equally decreased after lactose, 
casein, whey preloads as compared to glucose. These were 
consistent with differences in plasma ghrelin. The higher 
CCK responses found after whey and casein preloads 
correlated with satiety without interfering with EI. 
 
Bowen et al., 
2006b 
30 
prehypertensive 
or stage 1 
hypertensive 
subjects with BMI 
(kg/m
2
): control 
(29.6±4.4); active 
(28.3±4.5) 
 
randomized 
controlled, 
double-
blinded 
6 weeks 20 g/d  
unmodified 
whey protein 
(UMWP) 
20 g/d hydrolyzed whey 
protein (HWP) 
HWP decreased both systolic blood pressure and diastolic 
blood pressure in a population of prehypertensive or stage 
1 hypertensive overweight men and women. HWP 
significantly improved both low-density lipoprotein 
cholesterol and high-sensitivity C-reactive protein. 
Pins & 
Keenan, 
2006 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
28 obese men 
with BMI: 
32.5±0.6 kg/m
2
 
 
randomized 
controlled, 
cross-over, 
double-
blinded 
 
After 
beverage 
loading  
   
4 beverages (1.1 MJ) 
containing: 1) whey (50 g); 
2) fructose (50 g); 3) glucose 
(50 g); 4) whey (25 g) + 
fructose (25 g) 
 
Whey proteins caused a prolonged suppression of ghrelin 
and elevation of GLP-1 and CCK, which were decreased 
in combination with fructose, but glucose and insulin 
responses were similar in both groups. 
 
 
Bowen et al., 
2007 
39 subjects with 
BMI: 27.6±1.7 
kg/m
2
 
randomized 
controlled, 
cross-over 
experiment 
1: 4 h; 
experiment 
2: 7 h 
  Shakes containing: 1) 15 g 
whey protein (WP); 2) 15 g 
pea protein hydrolysate 
(PPH); 3) WP (7.5 g) + PPH 
(7.5 g); 4) 15 g milk protein 
(MP) 
 
Both WP and PPH induced greater satiety and fullness 
than MP and WP+PPH. A positive correlation between 
insulin and both CCK and GLP-1 was noted in WP group.  
Diepvens et 
al., 2008 
127 subjects (95 
women, 32 men; 
BMI 33.4±3.4 
kg/m
2
), 72 
completed the 
12-month study. 
 
randomized 
controlled, 
parallel-
design, 
double-
blinded 
12 months   Meal replacements 
containing 900 kJ/sachet 
and : 1) 15 g GMP-enriched 
whey protein isolate (GMP-
WPI); 2) 15 g skim milk 
powder (SMP) 
 
Both meal replacements exerted similar effects on the 
overall sustained 12 months weight loss and improvements 
in cardiovascular disease risk markers.  
Keogh & 
Clifton, 
2008 
48 subjects (31 
women) with 
BMI ≥ 27 kg/m2 
randomized 
controlled 
5-6 weeks of 
ER period 
followed by 
a 12 weeks 
of weight 
maintenance 
period 
  Weight loss was induced by 
a very low-calorie diet; 
during weight maintenance: 
1) maltodextrin (HC group); 
2) casein (HPC group); 3) 
whey (HPW group) 
supplements (2 x 25 g/d) 
were served respectively, 
with a low-fat diet. 
The low-fat, high protein (both whey and casein) displayed 
a better maintenance of weight loss than the low-fat, high 
carbohydrate diet, and did not adversely affect metabolic 
and cardiovascular risk factors in weight-reduced 
moderately obese subjects without metabolic or 
cardiovascular complications.  
Claessens et 
al., 2009 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
9 healthy 
women with 
BMI: 29.2±1.3 
kg/m
2
 
 
randomized 
controlled, 
cross-over, 
double-
blinded 
 
two 15-day 
trials 
separated by 
a ≥ 1-week 
washout 
period 
   
Each trial provided a total 
dietary protein intake about 
0.8 g/kg body weight/day; 
about half of the protein was 
administered as a 
supplement and consisted of 
either Protein A (a whey 
protein concentrate) or 
Protein B (a concentrated, 
fortified, collagen protein 
hydrolysate) 
 
 
The consumption of whey supplement reduced body 
weight. No changes were observed on body weight after 
consumption of the collagen supplement. The nitrogen 
balance was not different between the groups. 
 
Hays et al., 
2009 
10 subjects (3 
men) with BMI: 
33.6±4.8 kg/m
2
 
randomized 
controlled, 
acute 
After meal 50 g glucose 1) 50 g glucose + 5 g GILP 
protein; 2) 50 g glucose + 10 
g GILP protein; 3) 50 g 
glucose + 20 g GILP protein 
Adding GILP to an oral glucose bolus dose-dependently 
decreased blood glucose iAUC and averaged 4.6±1.4 
mmol.min/L per gram of GILP. 
 
Petersen et 
al., 2009 
20 men with 
BMI: 31.5 (SD 
3.0) kg/m
2
 
randomized 
controlled, 
double-
blinded, 
acute 
protein 
preloads 
first, 
followed by 
ad libitum 
lunch 
glucose control 4 different preloads 
containing : 1) 41.3 g 
minimally glycosylated 
GMP fraction; 2) 42.3 g 
glycosylated GMP fraction; 
3) 44.4 g GMP-depleted 
whey protein concentrate 
fraction 
 
The protein fractions in the dose used did not cause any 
reduction in food intake at the subsequent meal. In 
addition, they did not change the postprandial CCK 
concentrations. 
Keogh et al., 
2010 
70 subjects with 
BMI: 31.3±0.8 
kg/m
2
 
randomized 
controlled, 
parallel-
design 
12 weeks glucose control 
(27 g glucose) 
Supplement sachets: 1) 
whey protein isolate (27 g 
protein); 2) sodium caseinate 
(27 g protein) 
Whey proteins did not change body composition or serum 
glucose in comparison with either control or casein in 
overweight and obese subjects.  However, whey proteins 
improved fasting lipids and insulin levels in the same 
subjects.  
Pal et al., 
2010a 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
20 overweight 
or obese, 
postmenopausal 
women with 
BMI: 25-40 
kg/m
2
 (range) 
 
randomized 
controlled, 
single-
blinded, 
three-way 
cross-over 
 
 
3 weeks with a 
4-week washout 
period before 
commencement 
 
glucose 
control (45 g 
glucose ) 
 
Supplements containing: 
1) whey protein isolate (45 
g protein); 2) sodium 
caseinate (45 g protein) 
 
Whey protein reduced arterial exposure to smaller TG-
enriched lipoprotein particles in the postprandial period in 
overweight and obese, post-menopausal women as 
compared with glucose or casein. 
 
Pal et al., 
2010b 
70 subjects with 
BMI: 31.3±0.8 
kg/m
2
 
randomized 
controlled, 
single-
blinded, 
parallel-
design 
12 weeks period 
with a 4-week 
washout period 
before 
commencement 
glucose 
control (27 g 
glucose) 
1) sodium caseinate (27 g 
protein); 2) whey protein 
isolate (27 g protein) 
Both systolic (SBP) and diastolic blood pressure (DBP) 
significantly decreased compared to baseline at week 6 and 
week 12 in both whey and casein groups. As compared 
with control group, DBP decreased significantly in the 
whey and casein groups at week 12. In whey group, the 
augmentation index (AI) was significantly lower from 
baseline at 12 weeks. AI significantly decreased in whey 
group at 12 weeks as compared to control group. The 
supplementation of whey protein improved blood pressure 
and vascular function in overweight and obese subjects. 
 
Pal & Ellis, 
2010b 
18 healthy 
subjects with 
BMI: 27-32 
kg/m
2
 (range) 
randomized 
controlled, 
parallel-
design 
5-month study 
of 8-week 
controlled food 
intake followed 
by 12-week ad 
libitum intake 
control diet 
(15 % energy 
from protein, 
55 % energy 
from 
carbohydrate) 
1) mixed protein diet 
(30 % energy from mixed 
protein, 40 % energy from 
carbohydrate); 2) whey 
protein diet (15 % energy 
from mixed protein, 15 % 
energy from whey protein, 
40% energy from 
carbohydrate) 
 
The enhanced whey protein intake did not have any 
significant effects on weight loss or total fat loss. 
However, there were statistically significant differences in 
regional fat loss and in decreased blood pressure in whey 
protein group. 
Aldrich et 
al., 2011 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
73 overweight 
or obese 
subjects with 
BMI: 28-38 
kg/m
2
 (range) 
 
 
randomized 
controlled, 
double-
blinded 
 
23 weeks 
 
an 
isoenergetic 
amount of 
carbohydrate 
 
1) whey protein (56 g 
protein per day); 2) soy 
protein (56 g protein per 
day ) 
 
The subjects from the whey protein group exerted lower 
body weight, fat mass and smaller waist circumference and 
fasting ghrelin level after 23 weeks free-living period. 
 
Baer et al., 
2011 
161 subjects 
with BMI: 
26.3±3.6 kg/m
2
 
randomized, 
placebo-
controlled, 
multi-centre, 
double-
blinded, 
parallel-
design 
 
6-week run-in 
phase, followed 
by 12 weeks 
treatment phase 
placebo malleable protein matrix 
(MPM) 
The whey fermentation product MPM showed significant 
triglyceride-lowering properties in subjects with combined 
hypercholesterolemia and higher triglyceride levels. 
Berthold et 
al., 2011 
11 subjects with 
BMI: 30.3-42.0 
kg/m
2
 (range) 
randomized 
controlled, 
acute, cross-
over 
After meal up to 
4 h 
  a fat rich mixed meal with 
one of the following 
dietary protein 
supplements: 1) cod 
protein; 2) whey isolate; 3) 
gluten; 4) casein 
CCL5/RANTES initially increased after all meals, while 
the whey meal caused the smallest overall postprandial 
increase.  
MCP-1 was initially suppressed after all meals and the 
smallest overall postprandial suppression was noted after 
the whey meal. 
 
Holmer-
Jensen et al., 
2011 
31 overweight 
or obese, 
postmenopausal 
women with 
BMI: 33.7±4.9 
kg/m
2
 
randomized 
controlled, 
double-
blinded, 
parallel-
design 
6 months   a reduced calorie diet 
(1,400 kcal/day) with 
either of the supplements 
containing: 1) 2 x 25 g/day 
whey protein; 2) 2 x 25 
g/day maltodextrin 
(CARB)  
 
During caloric restriction, a higher whey protein intake 
maintained muscle relative to weight lost. This effect 
helped enhance physical function in older women. 
Mojtahedi et 
al., 2011 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
20 overweight 
or obese, 
postmenopausal 
women with 
BMI: 32.5±1.03 
kg/m2 
 
randomized 
controlled, 
three-way 
cross-over  
 
Over 3 weeks 
with a 4-week 
washout period 
before 
commencement 
 
glucose 
control (45 g 
glucose ) 
 
Supplements containing: 
1) whey protein isolate (45 
g protein); 2) sodium 
caseinate (45 g protein) 
 
No significant difference was observed in augmentation 
index, systolic or diastolic blood pressure within or 
between the glucose control, casein or whey protein 
groups. No significant group effects were noted on plasma 
inflammatory markers. This indicated that the health 
effects previously seen with chronic whey protein 
ingestion were better observed with the long-term 
consumption of whey proteins. 
 
 
Pal & Ellis, 
2011 
30 subjects with 
BMI: 29.0±0.7 
kg/m
2
 
randomized 
controlled, 
cross-over 
After drink 
loading. 3 days 
washout period 
Drink 
containing 
only 50 g 
isomaltulose 
(ISO) 
1) Drink containing 50 g 
ISO and 21 g whey/soy  
2) Drink containing 50 g 
ISO and 21g casein 
The combination of carbohydrate with whey proteins 
increased postprandial insulin levels, but reduced the 
actions of insulin in comparison with supplementing with 
casein proteins.  
 
Ang et al, 
2012 
203 overweight 
adolescents with 
BMI: 25.4 (SD 
2.3) kg/m
2
 
randomized 
controlled 
 
12 weeks  Drink containing 1) skim 
milk; 2) whey; 3) casein; 
4) water 
The high intakes of skim milk, whey, and casein increased 
BMI-for-age Z-scores in overweight adolescents. The high 
intakes of whey and casein increased insulin secretion in 
the same subjects. 
  
Arnberg et 
al., 2012 
12 subjects with 
BMI: 31.3±0.5 
kg/m
2
 
randomized 
controlled 
8 weeks  Daily 400 kcal solid food 
combined with 800 kcal 
of: 1) whey protein + 
essential amino acid meal 
replacement (EAAMR) 
2) competitive meal 
replacement (CMR) 
 
The whey proteins containing EAAMR promoted 
preferential adipose tissue reduction with modest loss of 
lean mass in elderly subjects during energy restriction. 
Coker et al., 
2012 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
171 subjects 
with BMI: 31.0 
(SD 4.1) kg/m
2
 
 
randomized, 
placebo-
controlled, 
multi-center, 
double-
blinded, 
parallel-
design 
 
 
3 months 
 
placebo  
yoghurt 
 
whey malleable protein 
matrix (MPM) yoghurt 
 
The fasting triglyceride concentrations in patients with the 
metabolic syndrome were significantly decreased after the 
consumption of whey MPM yoghurt twice a day over 3 
months. This treatment also improved multiple other 
cardiovascular risk factors i.e. fasting plasma glucose, 
blood pressure and body weight. 
 
Gouni-
Berthold et 
al., 2012 
11 obese non-
diabetic subjects 
with BMI: 30-
41.4 kg/m
2
 
(range) 
randomized 
controlled, 
acute, 
single-
blinded, 
cross-over 
 
After meal up to 
8 h 
  45 g proteins: 1) alpha-
lactalbumin; 2) whey 
isolate; 3) 
caseinoglycomacropeptide; 
4) whey hydrolysate 
Whey hydrolysate was associated with a significantly 
smaller postprandial suppression of non-esterified free 
fatty acids compared with other tested proteins. 
Holmer-
Jensen et al., 
2012 
17 slightly 
overweight male 
subjects with 
BMI: 29±4 
kg/m
2
 
randomized 
controlled, 
single-
blinded, 
cross-over 
After meal up to 
4 h 
  isocaloric meals containing 
one of the following 
drinks: 1) whey drink; 2) 
casein drink; 3) skimmed 
milk 
Milk inhibited subsequent EI as compared with isocaloric 
drinks containing only whey or casein. There was a 
signiﬁcant increase in lipid oxidation after casein drink 
intake as compared with whey. 
Lorenzen et 
al., 2012 
30 men with 
BMI: 25-30 
kg/m
2
 (range) 
randomized 
controlled, 
single-
blinded 
6 weeks No training or 
heavy physical 
activity 
1) Resistance training with 
whey consumption; 2) 
Resistance training with 
placebo consumption 
The combination of resistance training with whey 
consumption enhanced the beneficial effects of exercise 
alone on the antioxidant system in overweight subjects. 
Sheikholesla
mi Vatani & 
Ahmadi 
Kani Golzar, 
2012 
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Patient groups 
Study 
design 
Time range 
Intervention 
Main results References 
Control Treatment 
 
327 overweight 
and obese 
subjects with 
BMI: 30.0±2.8 
kg/m
2
 
 
randomized 
placebo- 
controlled, 
double-
blinded 
 
36 weeks 
  
Powder supplements 
containing: 1) 0 g; 2) 10 g; 
3) 20 g; 4) 30 g whey 
proteins 
 
The whey protein supplementation did not affect the 
exercise induced responses in body composition or indices 
of metabolic syndrome in overweight and obese adults. 
 
Weinheimer 
et al., 2012 
 
161 subjects 
BMI: 28.1±4.4 
kg/m
2
 in Whey 
protein group; 
29.4±4.8 kg/m
2
 
in 
Carbohydrates 
group 
 
 
randomized 
controlled, 
double-
blinded 
 
12 weeks 
   
Liquid supplementation 
taken after training 
containing: 1) whey 
protein 20 g; 2) isocaloric 
carbohydrate 20 g 
 
Compared to isocaloric carbohydrate, the whey protein 
supplementation did not lead to greater gains in lean body 
mass, strength and physical function in elderly people in 
this study. 
 
Arnarson et 
al., 2013 
11 obese non-
diabetic subjects 
with BMI: 30.3-
42.0 kg/m
2
 
(range) 
randomized 
controlled, 
acute, 
cross-over 
After meal, 8-h 
postprandial 
period. 2 weeks 
washout period 
 Fat rich mixed meal 
containing 45 g proteins. 
The protein sources: 1) 
cod; 2) whey isolate; 3) 
gluten; 4) casein 
The supplementation with whey proteins caused lower 
postprandial lipemia compared to the supplementation 
with cod and gluten, which indicated that long-term 
supplementation with whey proteins might be beneficial in 
the prevention of cardiovascular disease in obese non-
diabetic subjects. 
 
Holmer-
Jensen et al., 
2013 
 
a 
RE represents resistance exercise. EI represents energy intake. GILP represents glycemic index lowering peptide fraction. Data of BMI are presented either as mean±SEM,  
or mean (SD), or range.
31 
 
     It has been reported that whey proteins with calcium supplementation accelerated body weight and 
fat loss under energy restriction in mice as compared to casein (Pilvi et al., 2008). Consumption of 
whey proteins with calcium supplementation also decreased the serum insulin level and normalized 
the relative level of potential diabetogenic ceramides and diacylglycerols in mice subjected to energy 
restriction (Pilvi et al., 2008). In accordance with the results of Pilvi et al. (2008), it was reported that 
the mice fed the diet containing whey protein isolate had higher basal metabolic rates and less 
hepatosteatosis and insulin resistance as compared with controls (Shertzer et al., 2011). There is also a 
report that oral administration of whey proteins achieved an improvement in fatty infiltration in 
hepatocytes and a reduction of oxidative stress parameters in rats (Hamad et al., 2011). These findings 
were considered to indicate that a diet with whey protein isolate may be effective in slowing the 
development of fatty liver and type 2 diabetes.  
 
2.3.2 Metabolic syndrome and whey proteins 
 
The metabolic syndrome is a cluster of metabolic abnormalities including abdominal obesity, 
dyslipidemia, insulin resistance, and increased blood pressure, which reflects overnutrition, sedentary 
lifestyles, and resultant excess adiposity (Cornier et al., 2008). It is associated with other 
comorbidities, including non-alcoholic fatty liver disease, a prothrombotic state, a pro-inflammatory 
condition, and reproductive disorders (Cornier et al., 2008). It has been reported that a patient with 
metabolic syndrome has an increased risk of developing cardiovascular disease and type 2 diabetes 
(Grundy et al., 2005; Grundy, 2008). According to U.S. government health surveys conducted 
between 1999 and 2006, about 34 % of the adults in U.S. meet the criteria of the metabolic syndrome 
(Ervin, 2009; Mozumdar & Liguori, 2011). The worldwide increased prevalence of metabolic 
syndrome is largely due to the epidemic of obesity (Bruce & Hanson, 2010). Although the genetic 
background affects the development of metabolic syndrome, lifestyle intervention, including dietary 
control, play the main role in the long-term prevention (Grundy et al., 2005; Bruce & Hanson, 2010; 
Lindstrom et al., 2013; Orchard et al., 2013).  
    The intake of dairy products exerted beneficial effects on the risk of developing the metabolic 
syndrome (Grundy et al., 2005). It has been reported that a high consumption of dairy products (3-4 
servings per day) was associated with a  29 % decreased risk of developing the metabolic syndrome as 
compared with low consumption of dairy products (less than 2 servings per day) (Pittas et al., 2007). 
Recently a systematic review was conducted on 13 observational studies; seven of the studies detected 
an inverse association between dairy intake and metabolic syndrome, three found no association, and 
the other three reported mixed relationships between specific dairy foods and metabolic syndrome 
(Crichton et al., 2011). The intake of dairy products not only exerted the beneficial effects on the 
incidence of metabolic syndrome, but also on the risk factors for metabolic syndrome such as 
impaired fasting glucose level, diastolic blood pressure and BMI (Fumeron et al., 2011). In addition, 
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adequate dairy intake during weight maintenance reduced oxidative and inflammatory stress, which 
are commonly observed in association with the metabolic syndrome (Stancliffe et al., 2011).  
    Although the physiological mechanism behind the effects of dairy products on the metabolic 
syndrome have yet to be fully elucidated, several components, such as milk-fat, vitamin D, 
magnesium, and whey proteins, have been postulated to individually or collectively provide 
protection against this disease by modulating its individual components such as blood lipid levels, 
blood pressure, fasting glucose levels, and body composition (Pfeuffer & Schrezenmeir, 2007; 
Scholz-Ahrens & Schrezenmeir, 2006; Rice et al., 2011). There are studies revealing that whey 
protein intake was able to improve blood lipid profile, blood pressure control, insulin sensitivity and 
body composition, which were the risk factors associated with the metabolic syndrome (Westerterp-
Plantenga et al., 2009b; Hulmi et al., 2010; Pal et al., 2010a; Pal & Ellis, 2010b; Rice et al., 2011).   
 
2.3.3 Type 2 diabetes and whey proteins 
 
Diabetes is defined as a disability of the body to regulate its blood glucose level, which increases the 
risk of blindness, kidney disease, coronary heart disease, leg and foot amputations, stroke, 
hypertension, and nerve damage (Centers for Disease Control and Prevention, 2011). It has been 
classified into two main types i.e. type 1 diabetes, the insulin-dependent diabetes mellitus, and type 2 
diabetes, the non-insulin dependent diabetes mellitus (Centers for Disease Control and Prevention, 
2011). About 90-95 % of all diagnosed diabetics suffer from type 2 diabetes mellitus (Centers for 
Disease Control and Prevention, 2011). Type 2 diabetes is in association with older age, family 
history of diabetes, impaired glucose metabolism, obesity, physical inactivity, and race/ethnicity 
(Centers for Disease Control and Prevention, 2011). Although the cause of type 2 diabetes remains 
unclear, genetic, environmental and lifestyle factors are considered to be risk factors for this disease 
(Centers for Disease Control and Prevention, 2011). It has been proposed that diet (or medical 
nutrition therapy) can play an important role in successful management of type 2 diabetes (American 
Diabetes Association, 2008; Franz et al., 2010). In several studies, dairy food intake has been shown 
to display an inverse association with type 2 diabetes (Pittas et al., 2007; Tremblay & Gilbert, 2009; 
Elwood et al., 2010). In one meta-analysis of observational studies, the highest dairy intake (3 to 5 
servings per day) lowered the risk of type 2 diabetes by 14 % as compared with the lowest dairy 
intake (less than 1.5 servings per day) (Pittas et al., 2007). Recently, data from one systematic review 
and a meta-analysis of seven prospective studies showed similar effects of dairy consumption on type 
2 diabetes: the highest intake of dairy products achieved a significant reduction in the risk in adults as 
compared with the lowest intake (Tong et al., 2011). The highest dairy consumption reduced by 47 % 
the risk of type 2 diabetes in men in the Australian Diabetes, Obesity and Lifestyle study as compared 
with the lowest consumption (Grantham et al., 2013). A high dairy intake in adolescence may also 
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lower risk of type 2 diabetes in adulthood according to a prospective study in adult women (Malik et 
al., 2011).  
    Several dairy nutrients and components, including calcium, vitamin D, magnesium, trans-
palmitoleic acid and whey proteins, have been proposed to be involved in the reduction of risk of type 
2 diabetes achieved by high consumption of dairy products (Larsson & Wolk, 2007; Pittas et al., 2007; 
Tremblay & Gilbert, 2009; Akhavan et al., 2010; Mozaffarian et al., 2010; Gagnon et al., 2011). 
Whey protein supplementation at both breakfast and lunch increased insulin secretion and improved 
blood glucose control in type 2 diabetes (Frid et al., 2005). In comparison with casein, the ingestion of 
whey proteins induced greater post-prandial aminoacidemia and higher beta-cell secretion in type 2 
diabetes mellitus patients (Tessari et al., 2007). Preloading with whey proteins also markedly reduced 
postprandial glycemia in type 2 diabetes by stimulating insulin, incretin hormone secretion, and 
slowing gastric emptying (Ma et al., 2009). However, in one study investigating the effects of co-
ingestion of carbohydrate and protein on glucose and insulin responses in type 2 diabetic subjects, it 
was observed that the combination of carbohydrate with whey proteins increased postprandial insulin 
levels, but reduced the actions of insulin in comparison with supplementing with casein proteins (Ang 
et al., 2012). The authors proposed that the fast-absorbing protein mixture (whey) might not be 
recommended for glycemic control in type 2 diabetes (Ang et al., 2012). 
 
2.3.4 Other health effects of whey proteins 
 
Whey proteins have also shown other different physiological properties and biological activities: these 
range from antioxidant and immunomodulation to anti-carcinogenic and anti-inflammatory effects 
(Table 3) (for reviews, see Marshall, 2004; Yalcin, 2006; Krissansen, 2007).  
 
2.3.5 Possible mechanisms behind the anti-obesity effect of whey proteins  
 
2.3.5.1 Whey proteins and satiety 
 
An increased protein intake has been reported to enhance satiety and reduce energy intake in 
comparison with an intake of fats or carbohydrates (Anderson & Moore, 2004). Furthermore, a high 
protein diet has been shown to induce more feelings of satiety than the normal protein diet (Lejeune et 
al., 2006; Westerterp-Plantenga et al., 2006; Veldhorst et al., 2008; Westerterp-Plantenga et al., 
2009a). Thus, there has been a great interest in studying the relationship between milk proteins and 
satiety.    
    Several studies have investigated the effects of different protein sources on satiety (Hall et al., 2003; 
Anderson et al., 2004; Bowen et al., 2006b; Veldhorst et al., 2009; Pal & Ellis, 2010a). Whey proteins 
have been claimed to be more satiating than casein, soy, turkey and egg proteins (Hall et al., 2003; 
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Anderson et al., 2004; Veldhorst et al., 2009; Pal & Ellis, 2010a). However, some workers failed to 
observe any difference between whey and casein in terms of their effects on feelings of satiety 
(Bowen et al., 2006b). Whey and casein have been classified as fast and slow proteins respectively 
due to their digestion and absorption speed (Boirie et al., 1997; Dangin et al., 2002). It has been 
postulated that the satiety effect of milk products is a synergistic effect of whey (acting as ‘fast’ 
proteins) providing early and casein (acting as ‘slow’ proteins) providing overlapping but later signals 
(for review see Luhovyy et al., 2007). When compared with casein, the greater satiating effect of 
whey proteins could be explained by the higher plasma concentration of cholecystokinins (CCKs) and 
glucagon-like peptide-1 (GLP-1) found after whey digestion (Hall et al., 2003). Furthermore, the high 
concentration of leucine in whey may also contribute to its satiety effects. An intracerebroventricular 
administration of leucine or an increase in the amount of leucine in the diet inhibited food intake and 
body weight gain and enhanced glucose and cholesterol metabolism in both rat and mouse models 
(Cota et al., 2006; Zhang et al., 2007; Morrison et al., 2007); this effect was mediated through the 
activation of mTOR pathway in the hypothalamus (Morrison et al., 2007).     
 
2.3.5.2 The insulinotropic property of whey proteins 
 
The consumption of dairy products has been shown to reduce the risk of the metabolic syndrome and 
type 2 diabetes (see 2.3.2 and 2.3.3). It has been reported that an intake of whey protein in particular 
improves post-prandial glycaemic control (Nilsson et al., 2004; Frid et al., 2005; Tessari et al., 2007; 
Ma et al., 2009; Akhavan et al., 2010). The insulinotropic property of whey proteins has been 
proposed to be involved in several mechanisms.  
    Since they are classified as ‘fast’ proteins, the rapid digestion and absorption of whey proteins 
results in higher concentrations of amino acids in the blood stream after ingestion, and this can 
stimulate the secretion of insulin. The rapid absorption of certain insulinotropic amino acids 
(isoleucine, leucine, lysine, threonine, and valine) leads to a clear post-prandial glycaemic and 
insulinemic response (Nilsson et al., 2004). In comparison with other proteins, whey proteins contain 
a high concentration of branched-chain amino acids (BCAAs) e.g. isoleucine, leucine and valine, and 
this may contribute to its insulinotropic effect (Marshall, 2004). Whey proteins also increase the 
concentration of incretin hormones which enhance insulin secretion in a glucose-dependent manner 
(Drucker, 2006). The incretin hormones, such as glucagon-like peptide 1 (GLP-1) and gastric 
inhibitory polypeptide (GIP), are released after food ingestion; they are rapidly degraded via 
dipeptidyl peptidase IV (DPP-IV) in the gastrointestinal tract (Gunnarsson et al., 2006). Whey 
proteins have been reported to inhibit the activity of DPP-IV and to increase GLP-1 level, which leads 
to an overall increased insulin response (Gunnarsson et al., 2006).  
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2.4 Whey proteins manufacturing 
 
2.4.1 Traditional method 
 
Whey was previously considered simply as a by-product of cheese manufacture. Traditionally, cheese 
production starts with milk fat-to-protein standardization, including pasteurization or some other heat 
treatment. Additives, such as calcium chloride and copper sulphate, are added to milk since they 
confer different properties (Heino, 2009). After the addition of chymosin, the milk is coagulated to 
form a curd (coagulated milk). Then, the curd is cut and whey is partly removed from the cheese vat. 
After the addition of water to curd to dilute the lactose content, the curd is cooked and curd syneresis 
removes whey from the pieces of curd. The collected raw whey is then subjected to clarification 
(removal of casein fines), separation (removal of residual fat), pasteurization, and concentration (by a 
variety of methods e.g. reverse osmosis, nanofiltration, evaporation) (Outinen, 2010). This resulting 
product is then processed to generate different whey products (including whey proteins) in different 
ways such as ultrafiltration, demineralization, chromatography, and protein fractionation (Outinen, 
2010).   
 
2.4.2 Microfiltration method 
 
The microfiltration technique is a type of pressure driven membrane filtration: this is used to separate 
molecules, particles, or microbe from liquids (Heino, 2009). This technique has been widely used in 
mining, chemical, pharmaceutical, and food industry. Microfiltration has been postulated as being an 
excellent technique to remove whey from milk and it differs from the traditional cheese making 
process (Brans et al., 2004). When micellar casein micelles are concentrated via microfiltration, the 
milk microfiltrate permeate is called native whey and it contains whey proteins which are called 
native whey proteins (Heino, 2009). The native whey has a higher technological and economic value 
than the standard cheese whey (Maubois, 2002). Furthermore, when compared to cheese whey, the 
microfiltrated native whey is free of fat, cheese fines, bacteria, somatic cells, lactic acid, κ-casein and 
β-lactoglobulin complexes and cheese chymosin (Maubois, 2002; Ardisson-Korat & Rizvi, 2004), and 
it contains only a minimal amount of BSA, GMP and caseinomacropeptide (CMP) (Maubois, 2002; 
Ardisson-Korat & Rizvi, 2004; Heino et al., 2007).   
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3 Aims of the study 
 
Previous studies have shown that the intake of dairy products is related to a lower risk of type 2 
diabetes, metabolic syndrome and obesity. Whey proteins have been postulated to play an important 
role in the beneficial effects of dairy products on weight management, but the mechanisms behind this 
phenomenon remain unknown. Non-alcoholic fatty liver disease has been reported to be strongly 
associated with obesity. There is growing evidence to suggest that the weight loss by energy 
restriction decreases liver fat and adipose tissue inflammation but again the mechanisms remain 
unclear. The aim of the present study was to investigate the potential of different whey proteins and 
their mechanisms of actions to prevent and help in the treatment of diet-induced obesity and its 
consequences in an experimental model of diet-induced obesity. 
 
The special aims of the study were the following: 
 
1. To investigate the metabolic effects of a novel whey protein isolate, rich in lactoperoxidase, 
lactoferrin, growth factors and immunoglobulins on diet-induced obesity and obesity related 
disorders in C57Bl/6J mice during weight loss and weight regain. 
 
2. To evaluate the effects of lactoferrin supplementation on diet-induced obesity and its 
consequences in C57Bl/6J mice during weight loss and weight regain. 
 
3. To compare the effects of α-lactalbumin and amino acid mixtures with equivalent amino acid 
profiles on diet-induced obesity in C57Bl/6J mice during weight loss and weight regain, and 
to attempt to characterize the mechanisms which could explain the anti-obesity property of α-
lactalbumin. 
 
4. To assess the metabolic effects of a novel microfiltered native whey protein, acquired by 
filtration through polymeric membranes, on diet-induced obesity in C57Bl/6J mice during 
weight gain and weight loss, and furthermore to compare these effects with those obtained 
with α-lactalbumin in the same animal model.  
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4 Materials and methods 
 
4.1 Study design 
 
All of the four studies were conducted in C57Bl/6J male mice, a well-established animal model of 
diet-induced obesity (Surwit et al., 1988; Collins et al., 2004; Koza et al., 2006; Kanasaki & Koya, 
2011). This mouse strain develops obesity and insulin resistance when subjected to high-fat feeding. 
Therefore, these mice can serve as a diet-induced obesity experimental animal model of obesity 
research. 
    All of the four studies investigated the effects of different whey proteins on diet-induced obesity 
during three different phases of obesity (Table 5), i.e. weight gain (Study IV (i)), weight loss (Studies 
I, II, III, and IV (ii)), and weight regain (Studies I, II, and III). Study I investigated the effects of whey 
protein isolate (WPI) on obesity as well as the development of fatty liver during the weight loss and 
the weight regain phases. Study II evaluated the effects of lactoferrin on obesity and fatty liver 
formation during the weight loss and the weight regain phases. Study III compared the effects of α-
lactalbumin to the amino acid mixture with equal amino acid composition on obesity during the 
weight loss and the weight regain phases. Study IV focused on the effects of microfiltered native 
whey on obesity during the weight gain (Study IV(i)) and the weight loss (Study IV(ii)) phases.  
 
Table 5 The tested proteins and study phases in all four studies in the thesis. 
 
 Tested whey proteins 
Study phases 
  Weight gain Weight loss Weight regain 
Study I Whey protein isolate (WPI) No Yes Yes 
Study II Lactoferrin No Yes Yes 
Study III α-Lactalbumin No Yes Yes 
Study IV Microfiltered native whey Yes Yes No 
 
 
4.2 Experimental animals 
 
All the studies were carried out in C57Bl/6J male mice at the age of 6 weeks (Studies I, II and III) or 7 
weeks (Study IV (i) and (ii)), which were purchased from Charles River Europe (Sulzfeld, Germany). 
The mice were housed five per cage in a standard experimental animal laboratory, illuminated from 
7:00 to 19:00, temperature 22 ± 1 °C. The protocols were approved by the Animal Experimentation 
Committee of the University of Helsinki, Finland and the principles of laboratory animal care (NIH 
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publication no. 85-23, revised 1985) were followed. The mice had free access to tap water during the 
experiments.  
    After a one-week acclimatization period, the mice were fed with the high-fat diets for 100 days 
(Study IV(i)), 150 days (Study IV(ii)), 200 days (Studies I and II) or 250 days (Study III). In Studies I, 
II, III and IV(ii), the mice were first put on a standard high-fat diet (fat containing 60% of the diet 
energy and casein serving as the only protein source) (D12492, Research Diets Inc., New Bunswick, 
NJ, USA) (Table 6) for 100 days (Studies I, II, and IV (ii)) or 150 days (Study III) ad libitum feeding 
to induce obesity. Then, the body weight-matched mice were divided into treatment groups, fed 
different high-fat diets (Table 6) and subjected to energy restriction for 50 days (weight loss phase), in 
which the energy intake was reduced to 70% of the energy intake of the ad libitum feeding. In Studies 
I, II and III, some of the mice were sacrificed after the weight loss phase and the rest of the mice were 
kept on the same diets fed ad libitum for another 50 days (weight regain phase). In Study IV (i), the 
body weight-matched mice were fed different high-fat diets from the beginning of ad libitum feeding 
for 100 days (weight gain phase). Reference values for some parameters used in the studies were 
taken from additional age-matched obese mice fed casein-based high-fat diet and lean mice fed 
normal low-fat chow ad libitum starting immediately after weaning. 
 
4.3 Diets and groups 
 
All the diets were manufactured by Research Diets Inc. (New Brunswick, NJ, USA). The diets were 
produced on a standard high-fat diet (D12492), where fat contains 60% of the diet energy. The protein 
source and calcium amount (in Study III) of the testing diets were modified based on the study 
designs. The microfiltered native whey protein was produced by microfiltration technology with 
polymeric membranes and its composition was analyzed in Valio Ltd. (Helsinki, Finland). All test diet 
compositions and protein amino acid profiles are given in Tables 6 and 7. The protein source of the 
AA+Ca diet was an amino acid mixture with an equivalent amino acid profile compared to α-
lactalbumin (Table 6). Leucine (Leu), aspartate (Asp) and tryptophan (Trp) were enriched in the α-
lac(2xLeu)+Ca and the α-lac(2xAsp and Trp)+Ca diets. In the α-lac(2xLeu)+Ca diet, the final amino 
acid concentration of Leu was 2-fold as compared to the α-lac+Ca diet. In the α-lac(2xAsp and 
Trp)+Ca diet, the final amino acid concentration of Asp and Trp was 2-fold as compared to the α-
lac+Ca diet. The composition of WPI and microfiltered native whey protein is described in Table 8. 
The lean control groups in Studies I and II were fed with a low-fat rodent chow diet (RMI (E) FG 
SQC 811004, SDS, NOVA-SCB, Sweden). The powdered diets were all moistened with tap water (50 
ml/kg in casein, 60 ml/kg in WPI 5%, 90 ml/kg in WPI 50%, 90 ml/kg in WPI 100%, 140 ml/kg in α-
lac + Ca, 80 ml/kg in AA + Ca, 130 ml/kg in α-lac(2xAsp and Trp) + Ca, 155 ml/kg in α-lac(2xLeu) + 
Ca, 60 ml/kg in lactoferrin 15%, 155 ml/kg in microfiltered native whey, 145 ml/kg in α-lactalbumin), 
mixed in an industrial dough mixer and packed in one-day portions and stored at -20°C.
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Table 6 Diet composition in the thesis. 
 
  Casein WPI 5% 
WPI 
50% 
WPI 
100% 
Lactoferrin 
supplementation 
α-Lac + 
Ca 
AA + Ca 
α-Lac 
(2xAsp 
and Trp) 
+ Ca 
α-Lac 
(2xLeu) 
+ Ca 
MFNW α-Lactalbumin 
Protein (g)                       
-Casein 200 189.83 98.3 0 169.49 0 0 0 0 0 0 
-MG2785 0 9.42 94.21 188.4 0 0 0 0 0 0 0 
-Lactoferrin 0 0 0 0 29.18 0 0 0 0 0 0 
 -α-Lactalbumin 0 0 0 0 0 190.82 0 165 167.6 0 190.82 
-Crystalline amino acids 0 0 0 0 0 0 178.6 26.8 21.4 0 0 
-Microfiltered native whey 0 0 0 0 0 0 0 0 0 196.7 0 
Maltodextrin 10 (g) 125 125 125 125 125 125 125 125 125 125 125 
Sucrose (g) 71.21 71.21 71.1 71.1 69.4 69.37 70.32 69.5 69.48 70.62 69.37 
Cellulose (BW200) (g) 50 50 50 50 50 50 50 50 50 50 50 
Soya bean oil (g) 25 25 25 25 25 25 25 25 25 25 25 
Lard (g) 245 245 244.7 244.4 245 244.61 245.56 244.73 244.72 245.6 244.61 
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  Casein WPI 5% 
WPI 
50% 
WPI 
100% 
Lactoferrin 
supplementation 
α-Lac + 
Ca 
AA + Ca 
α-Lac 
(2xAsp 
and Trp) 
+ Ca 
α-Lac 
(2xLeu) 
+ Ca 
MFNW α-Lactalbumin 
 
Calcium phosphate, 
DiBasic (g) 
 
13 
 
13.25 
 
16.25 
 
19.25 
 
14 
 
0 
 
0 
 
0 
 
0 
 
11.91 
 
0 
Calcium carbonate (g) 5.5 5.3 3 0.5 4.7 34.91 34.78 34.9 34.87 4.49 14.67 
Potassium phosphate, 
MonoBasic (g) 
0     19.7 19.97 19.73 19.79 6.54 19.15 
Potassium citrate, 1 H2O 
(g) 
16.5 16.5 16.2 16 16.3 1.33 1.08 1.3 1.25 9.67 1.3 
Magnesium Oxide (g) 0     0.02 0.03 0.03 0.03   
Sodium Chloride (g) 2.59     0.9 5.38 1.5 1.45 1.89 0.8 
 
           
Energy (kcal/g dry weight) 5.1 5.1 5.2 5.2 5.2 5.1 5.1 5.1 5.1 5.2 5.2 
Protein (% energy) 18 18 18 18 18 18 18 18 18 18 18 
Carbohydrate (% energy) 21 21 21 21 21 21 21 21 21 21 21 
Fat (% energy) 61 61 61 61 61 61 61 61 61 61 61 
Ca (%) 0.79 0.79 0.79 0.79 0.79 1.8 1.8 1.8 1.8 0.79 0.79 
P (%) 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.6 0.59 
K (%) 0.77 0.77 0.77 0.77 0.77 0.79 0.79 0.79 0.79 0.78 0.79 
Na (%) 0.13 0.13 0.13 0.13 0.13 0.28 0.28 0.28 0.28 0.14 0.28 
 
           
Study I, II, III, 
IV 
I I I II III III III III IV IV 
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Table 7 Amino acid profile of the proteins used in the thesis. 
 
  
Casein 
(g/100 protein) 
WPI 
(g/100 protein) 
Lactoferrin 
(g/100 protein) 
α-Lactalbumin 
(g/100 protein) 
Microfiltered native whey 
(g/100 protein) 
 
Alanine 
 
2.9 
 
4.2 
 
6.9 
 
2 
 
5 
Arginine 3.4 7.2 7.5 1.3 2.7 
Aspartic acid 6.9 8.6 11.6 16.4 12.9 
Cystine 0.7 10.3 4.1 4.8 3.7 
Glutamic acid 21.7 11.1 12 12.6 20.9 
Glycine 1.7 3.4 4.3 2.7 2 
a
Histidine 2.6 2.6 2 3 2.2 
a
Isoleucine 4.3 3.2 2.5 6 6.6 
a
Leucine 9 8.5 9.8 10.8 13.5 
a
Lysine 7.5 6.7 9.3 10.9 11 
a
Methionine 2.9 1.2 0.8 1 2.3 
a
Phenylalanine 4.8 5.2 5.2 4.1 3.9 
Proline 10.1 5.7 4.6 3.3 5.1 
Serine 5.7 5.2 5.2 3.4 4.8 
a
Threonine 4.1 5.1 5.3 4.3 5.3 
a
Tryptophan 1.2 1.6 2.7 4.8 2.5 
Tyrosine 5.2 4.6 4.3 4.4 3.8 
a
Valine 5.3 4.7 5.7 4.3 5.6 
 
a Essential Amino Acids 
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Table 8 The composition of WPI and microfiltered native whey protein.  
 
 
Component Amount Unit 
 
WPI 
 
Protein (TNx6.38) 
 
97.9 
 
% dry matter 
Lactoperoxidase 49.5 % dry matter 
Lactoferrin 15.5 % dry matter 
IgG 7.2 % dry matter 
IgA 6.2 % dry matter 
Minor proteins 19.6 % dry matter 
IgF-1 2.1 mg/100g dry matter 
TGF-beta-2 5.2 mg/100g dry matter 
Fat 0.3 % dry matter 
Carbohydrates 0.1 % dry matter 
Ash 1.0 % dry matter 
Sodium 319.6 mg/100g dry matter 
Potassium 24.7 mg/100g dry matter 
Calcium 64.9 mg/100g dry matter 
Magnesium 13.4 mg/100g dry matter 
Phosphorus 30.9 mg/100g dry matter 
Chloride 1030.9 mg/100g dry matter 
    
Microfiltered 
native whey 
Protein ((N-NPN)x6.38) 97.2 % dry matter 
α-Lactalbumin 23.9 % of protein 
β-Lactoglobulin 65.2 % of protein 
Fat 0.2 % of dry matter 
Lactose 0.4 % of dry matter 
Ash 2.3 % of dry matter 
Sodium 155 mg/100g dry matter 
Potassium 326 mg/100g dry matter 
Calcium 416.9 mg/100g dry matter 
Magnesium 92.5 mg/100g dry matter 
Phosphorus 192.4 mg/100g dry matter 
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4.4 Body weight and energy intake measurements 
 
Body weight was monitored once per week and food consumption on a daily basis with a standard 
table scale (Ohaus Scour
TM
 Pro, SP4001, Nänikon, Switzerland). The energy intake was calculated 
according to food consumption and nutritional data. In Study IV, weight gain and weight loss were 
determined from body weight before and after the weight gain (WG) and the weight loss (WL) phases, 
using Eq. (1) and (2). 
 
Weight gain (%) = 100 x [(weight after WG- weight before WG)/weight before WG] (1) 
Weight loss (%) = 100 x [(weight before WL- weight after WL)/weight before WL] (2) 
 
4.5 Dual-energy X-ray absorptiometry (DEXA) measurement 
 
The body fat content and lean body mass (LBM) were measured by dual-energy x-ray absorptiometry 
(DEXA, Lunar PIXImus, GE Healthcare, Chalfont St. Giles, UK) after the weight gain, before and 
after the weight loss, and after the weight regain phases. During the measurement, the mice were 
under anaesthesia. In Study IV, fat loss and lean body mass maintenance (LBMM) were determined 
from body fat and LBM before and after weight loss phase, using Eq. (3) and (4). 
 
Fat loss (%) = 100 x [(fat content before WL- fat content after WL)/fat content before WL] (3) 
LBMM (%) = 100 x (LBM after WL/LBM before WL) (4) 
 
4.6 Oral glucose tolerance test 
 
The oral glucose tolerance test (OGTT) was performed on the mice after 6 hours of fasting at the end 
of the weight gain, the weight loss and the weight regain phases. Glucose (glucose dosage 1g/kg given 
as 20% glucose solution) was administered to the mice by gavage. Blood glucose was measured with 
a glucose meter (Super Glucocard
TM
 II, GT-1630, Arkray Factory Inc., Shiga, Japan) on blood 
samples taken from the tail vein at time points 0, 15, 30, 60 and 90 min after gavage. The areas under 
the curve (AUC) (blood glucose x time) were calculated as well.  
 
4.7 Faecal sample collection (Studies I, II and III) 
 
At the end of both the weight loss and the weight regain phases, the mice were housed in metabolic 
cages for 24 h. Food and water intakes were recorded. The faecal samples were collected. The faeces 
were weighed and stored at -70°C until further assayed.  
44 
 
4.8 Tissue sample preparation 
 
At the end of weight gain, weight loss and weight regain phases, the mice were rendered unconscious 
with CO2/O2 (95%/5%) (AGA, Riihimäki, Finland) and decapitated. The subcutaneous, epididymal, 
abdominal and perirenal fat pads (in Studies I, II, III and IV), liver (in Studies I and II) and skeletal 
muscle (musculus quadriceps femoris) (in Study II) were removed, washed with saline, blotted dry 
and weighted. The total and visceral fat weights were calculated using Eq. (5) and (6) individually. 
Tissue samples were snap-frozen in liquid nitrogen and stored at -80°C until further analyzed. In 
Studies I and II, the distal end of perirenal fat pad and the liver samples for histology were fixed in 
10% formalin and embedded in paraffin with routine techniques. In Study I, blood samples were taken 
into plastic tubes, and serum was separated by centrifugation at 960 x g at 4°C for 20 min.  
 
Total fat weight = subcutaneous + abdominal + epididymal + perirenal fat weights (5) 
Visceral fat weight = abdominal + epididymal + perirenal fat weights (6) 
 
4.9 Liver histology (Studies I and II)  
 
In Study I and II, formalin fixed, paraffin embedded liver sections (4 μm) were cut with a microtome. 
Liver sections were stained with hematoxylin and eosin (H&E) stain and evaluated under a 
conventional light microscope in a ‘blinded’ fashion. The samples were subjected to a semi-
quantitative histological scoring which was slightly modified from the non-alcoholic steatohepatitis 
(NASH) Clinical Research Network scoring system for Non-alcoholic fatty liver disease (Kleiner et 
al., 2005; Pilvi et al., 2008; Tiniakos et al., 2010). The scoring system is feature based and derived 
from individual scores for lobular inflammation, fibrosis, hepatocellular ballooning, and steatosis, 
which reflect the major histological lesions encountered in NASH (Kleiner et al., 2005; Tiniakos et al., 
2010).  
 
4.10 Adipocyte cross-sectional area (Studies I, II and IV) 
 
In Studies I, II and IV, the perirenal fat sections (4 µm) were stained with Hematoxylin and eosin 
(H&E) stain. The adipocyte cross-sectional area was determined in eight fields from each sample (In 
Studies I and II, n=5 in each group; In Study IV, n=8-10 in each group) by Leica QWin Standard-
software (Leica Microsystems Imaging Solutions Ltd, Cambridge, UK). 
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4.11 Biochemical measurements  
 
4.11.1 Serum lipopolysaccharide (LPS) (Study I) 
 
In Study I, serum lipopolysaccharide (LPS) concentration was measured by a Limulus amoebocyte 
lysate chromogenic end point assay from 1:5 diluted samples according to the instructions of the 
manufacturer (Hycult Biotechnology, Uden, The Netherlands). 
 
4.11.2 Apparent fat absorption (Studies I, II and III) 
 
In Studies I, II and III, the faecal fat content was determined by the Schmid-Bondzynski-Ratzlaff 
method ((NMKL), 1989). The apparent fat absorption (%) was calculated based on fat intake and 
faecal fat content using Eq. (7). 
 
Apparent fat absorption =100 x [(fat intake-faecal fat content)/fat intake] (7) 
 
4.12 Western Blotting (Studies I and II) 
 
In Studies I and II, samples from liver were homogenized using a Bertin Precellys 24 homogenizer 
(Bertin Technologies, Aix en Provence, France) and ceramic beads (Precellys CK14, Bertin 
Technologies) according to a protocol consisting of 5000 rpm for 50 s repeated twice. The proteins 
were isolated with lysis buffer (NaCl 136mM, Na2HPO4 8 Mm, KCl2 2.7mM, KH2P4 1.46 Mm, 
Tween 20 0.001%, and complete protease inhibitors (Roche Diagnostics, Neuilly-Sur-Seine, France)). 
During the immunoblotting, 20 μg of the total protein per lane was loaded and separated by 8% 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred 
to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P®, Millipore, Bedford, MA, USA). 
After blocking in 5 % non-fat milk-TBS-0.01 % Tween-20® buffer, the membranes were probed with 
the dilutions of the primary antibodies including anti-SIRT1, S6, phospho-S6, AMP-activated protein 
kinase α (AMPKα), phospho-AMPKα, anti-SIRT3 and α-tubulin (Table 9). Alpha-tubulin (Abcam, 
Cambridge, UK) served as a loading control at dilution 1: 2000. The horseradish peroxidase-
conjugated anti-rabbit secondary antibody (Chemicon, Temecula, CA, USA) was performed at 
dilution 1:5000. The localization of horseradish peroxidase was detected with the enhanced 
chemiluminescence solution (ECLplus, Amersham Biosciences, Buckinghamshire, UK). The protein 
expression was visualized by using FLA-9000 fluorescent image analyzer (Fujifilm Corp, Tokyo, 
Japan). 
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4.13 Quantitative real-time RT-PCR (Studies I and II) 
 
In Studies I and II, total RNA from the perirenal fat pads and skeletal muscle were collected with 
TRIzol (Invitrogen, Carlsbad, Calif., USA), treated with DNAse I (deoxyribonuclease 1, Sigma 
Chemicals, St Louis, MO., USA). One µg total RNA was reverse transcribed to cDNA in the presence 
of transcription enzyme by ImProm-II
TM
 Reverse Transcription System (Promega, Madison, WI, 
USA). One µl of cDNA was subjected to a quantitative real time polymerase chain reaction by 
Lightcycler instrument (Roche Diagnostics, Neuilly sur Seine, France) for the detection of leptin, 
plasminogen activator inhibitor-1 (PAI-1), monocyte chemoattractant protein-1 (MCP-1) and 18S 
mRNAs. The ribosomal 18S served as a housekeeping gene. The samples were amplified with 
FastStart DNA Master SYBR Green 1(Roche Diagnostics) based on the protocol of the manufacturer 
in the presence of 0.5 µM of the primers listed in Table 10. The quantities of the PCR products were 
quantified with an external standard curve which was amplified from the purified PCR product. 
 
4.14 Statistical analysis 
 
Data are presented as mean ± SEM. Statistically significant difference in mean values were tested by 
ANOVA followed by Dunnett’s test (Study I), Newman-Keuls test (Studies III and IV), and Student’s 
t-test (Study II). The difference was considered significant when P<0.05. The data were analyzed 
using GraphPad Prism, version 4.02 (GraphPad Software, Inc., San Diego, CA, USA). 
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Table 9 Western blotting primary antibodies, loading control and their dilutions used in the thesis. 
 
  Name  Producer Dilution 
 
Primary antibodies 
 
anti-SIRT1  
 
Upstate, Lake Placid, New York, USA 
 
1:1000 
  S6  Cell Signaling, Beverly, MA, USA 1:2000 
  phospho-S6 (Ser240/244)  Cell Signaling, Beverly, MA, USA 1:2000 
  AMP-activated protein kinase α(AMPKα)  Cell Signaling, Beverly, MA, USA 1:1000 
  phospho-AMPKα (Thr172)  Cell Signaling, Beverly, MA, USA 1:1000 
  anti-SIRT3  Abcam, Cambridge, UK 1:500 
Loading control α-tubulin  Abcam, Cambridge, UK 1:2000 
 
 
 
 
Table 10 Quantitative real-time RT-PCR primer sequences used in the thesis (Studies I and II). 
 
Primer Direction Sequence 
 
leptin 
 
forward 
 
AGACCGGGCAAGAGTG 
reverse GCCATAGTGCAAGGTT 
 
  
plasminogen activator inhibitor 1 (PAI-1) forward ACAGCCTTTGTCATCTCAGCC 
reverse CCGAACCACAAAGAGAAAGGA 
 
  
monocyte chemoattractant protein 1 (MCP-1) forward CGGAACCAAATGAGATCAG 
reverse TCACAGTCCGAGTCAC 
 
  
18S forward ACATCCAAGGAAGGCAGCAG 
reverse TTTTCGTCACTACCTCCCCG 
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5 Results 
 
5.1 Changes in body weight  
 
Weight gain phase (Study IV(i) 
 
In Study IV, both MFNW and α-lactalbumin inhibited body weight gain during 100 days high-fat 
feeding as compared to casein (Fig. 2). The final body weight in the α-lactalbumin group (31.9±1.0 g) 
was 14.3% lower than in MFNW group (37.2±1.1 g). The weight gain in α-lactalbumin group was 
approximately only 1/3 of the weight gain observed in MFNW group (Fig. 2). 
 
Weight loss phase (Studies I, II, III and IV(ii)) 
 
In Study I, WPI dose-dependently enhanced the body weight loss under ER in comparison to casein 
(Fig. 2). In Study II, the final body weight in the LF supplementation group was 9.5 % lower than in 
the casein group after weight loss (Fig. 2). In Study III, the AA+Ca diet achieved the greatest effect 
on accelerating weight loss under ER (Fig. 2). After weight loss, the final body weights in the AA+Ca 
(P<0.001) and the α-lac+Ca (P<0.05) groups were 21.1 % and 15.1 % lower than that in the casein 
group, respectively (Fig. 2). In Study IV, no significant differences were observed between groups 
with respect to body weight at the end of weight loss phase (ANOVA P=0.566).  
 
Weight regain phase (Studies I, II, and III) 
 
In Study I, WPI dose-dependently prevented weight regain as compared to casein (Fig. 2), although 
only the difference of final body weight between WPI 100 % (35.2±1.9 g) and casein groups 
(43.4±0.8 g) reached statistical significance (P<0.01). In Study II, LF supplementation inhibited the 
weight regain as compared to casein during the weight regain phase (Fig. 2). No significant 
differences were observed in any of the groups with respect to body weight after weight regain in 
Study III (ANOVA P=0.679).  
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Fig. 2 Difference in mean body weight in comparison with casein control group (%) at the end of the 
weight gain, the weight loss and the weight regain phases. 
 
5.2 Changes in amount of body fat, different adipose tissue and adipocyte size 
 
Weight gain phase (Study IV(i)) 
 
In Study IV, both MFNW (P<0.05) and α-lactalbumin (P<0.001) efficiently decreased the body fat 
content as compared to the casein diet at the end of weight gain phase (Fig. 3). The body fat 
percentage after weight gain in the α-lactalbumin group was also lower than in the MFNW group 
(P<0.05). The effects of MFNW and α-lactalbumin on total fat pad weights were in line with those 
observed for body fat content (Fig. 4). Both MFNW and α-lactalbumin decreased the size of 
adipocytes as compared to casein after weight gain, when measured via the adipocyte cross-sectional 
area (Fig. 5). As compared with MFNW (4951±597 μm2), the adipocyte size was 38.3 % smaller in 
the α-lactalbumin (3057±257 μm2) group (P<0.05). 
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Fig. 3 Difference in mean body fat percentage in comparison with casein control group (%) at the end of 
the weight gain, the weight loss and the weight regain phases. 
 
Weight loss phase (Studies I, II, III, and IV(ii)) 
 
In Study I, the body fat content was dose-dependently decreased by WPI as compared to casein after 
ER (Fig. 3). The body fat content was reduced in all treatment groups as compared with the casein 
group in both Studies II and III (Fig. 3), although the differences between casein (30.3±3.4 %) and the 
amino acid supplementation groups (α-lac(2xAsp and Trp)+Ca: 22.5±2.8 %; α-lac(2xLeu)+Ca: 
22.7±2.2 %) in Study III in the final body fat percentage did not reach statistical significance.  
    In Study I, the weights of total fat pad were significantly lower in all WPI groups as compared to 
that in the casein group (Fig. 4) (ANOVA P=0.009). In Study III, all of the tested whey protein diets 
successfully decreased the total fat pad accumulation as compared to casein (Fig. 4) (ANOVA 
P=0.019).  
    Adipocyte size after weight loss was measured as adipocyte cross-sectional area in Studies I, II and 
IV. In Study I, the adipocyte size was significantly smaller in all WPI groups as compared with that in 
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the casein group after weight loss (Fig. 5) (P<0.01 in all WPI groups when compared to the casein 
group). In Study IV, both MFNW and α-lactalbumin tended to decrease the adipocyte size in 
comparison to the casein diet after weight loss, but the difference was not statistically significant (Fig. 
5) (Study IV ANOVA P=0.051).  
 
 
 
Fig. 4 Difference in mean weight of total fat pad in comparison with casein control group (%) at the end 
of the weight gain, the weight loss and the weight regain phases. 
 
Weight regain phase (Studies I, II, and III) 
 
In Study I, WPI dose-dependently attenuated fat accumulation as compared to casein during weight 
regain phase (Fig. 3). The total fat percentage in the casein group (40.7±1.7 %) was even higher than 
the level found in age-matched obese mice (33.3±3.3 %) fed continuously ad libitum with the casein 
diet after the weight regain phase. It is interesting that in both Studies I and II, the total fat percentage 
in WPI 100 % group (after the weight loss phase: 21.4±1.9 %; after the weight regain phase: 
19.2±3.4 %) and LF supplementation group (after the weight loss phase: 24.7±2.8 %; after the weight 
regain phase: 23.8±4.4 %) remained at the same level as that observed after the weight loss phase.  
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    The weights of total fat pad were lower in the WPI groups than in the casein group after the weight 
regain phase in Study I (ANOVA P=0.001), although the difference between WPI 50% and casein 
group was not statistically significant (Fig. 4). In Study II, LF supplementation markedly reduced total 
fat pad weights as compared to casein (Fig. 4) (t-test P=0.005).  
 
 
 
Fig. 5 Difference in mean adipocyte size in comparison with casein control group (%) at the end of the 
weight gain, the weight loss and the weight regain phases. 
 
    Adipocyte size after weight regain was measured as the adipocyte cross-sectional area in Studies I 
and II (Fig. 5). Adipocyte size was significantly smaller in all WPI and LF groups compared with that 
in the casein group after weight regain (Study I P<0.05 in all WPI groups when compared to the 
casein group; Study II t-test P<0.0001). 
 
5.3 Changes in lean body mass (LBM) 
 
Weight gain phase (Study IV(i)) 
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The LBM in the MFNW group (26.55±0.73 g) tended to be higher than in either α-lactalbumin 
(25.54±0.67 g) or casein (25.48±0.58 g) groups after the weight gain phase in Study IV. 
 
Weight loss phase (Studies I, II, III, and IV(ii)) 
 
In Studies I, II, and IV, no significant difference was observed in LBM in any of the treatment groups 
as compared to casein group at the end of weight loss phase (Fig. 6) (Study I ANOVA P=0.243; 
Study II t-test P=0.299; Study IV ANOVA P=0.734). In Study III, as compared with age-matched 
obese mice fed ad libitum with casein-based high-fat diet, energy restriction decreased the LBM in all 
groups at the end of weight loss phase (ANOVA P<0.01). It is of great interest that only AA+Ca and 
MFNW decreased the LBM, whereas the other diets increased the LBM as compared to casein under 
ER (Fig. 6). 
 
 
 
Fig. 6 Difference in mean LBM in comparison with casein control group (%) at the end of the weight gain, 
the weight loss and the weight regain phases. 
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Weight regain phase (Studies I, II, and III) 
 
A dose-dependent manner towards increased LBM by WPI was noted after weight regain phase in 
Study I, although the difference was not statistically significant (Fig. 6) (ANOVA P=0.090). In 
Studies II and III, no significant differences were found in all treatment groups in LBM when 
compared to casein group, although the LBM in the LF supplementation group tended to be higher 
than in the casein group (Fig. 6) (Study II t-test P=0.067; Study III ANOVA P=0.913). Interestingly, 
only the amino acid supplementation groups (α-lac(2xAsp and Trp)+Ca; α-lac(2xLeu)+Ca) decreased 
the LBM, whereas the other diets increased the LBM as compared to casein after weight regain (Fig. 
6). 
 
5.4 Oral glucose tolerance test (OGTT) 
 
OGTT was performed on the mice at the end of the weight gain, the weight loss and the weight regain 
phases. The area under curve (AUC) (blood glucose level x time) was also calculated. 
 
Weight gain phase (Study IV(i)) 
 
In Study IV, no differences among the groups were observed in fasting blood glucose level (ANOVA 
P=0.90) or the AUC at the end of weight gain phase (ANOVA P=0.33). 
 
Weight loss phase (Studies I, II, III, and IV(ii)) 
 
In Study IV, the mice in ER MFNW group displayed lower fasting blood glucose level than in the ER 
α-lactalbumin group (ANOVA P=0.036). No differences were detected among the groups in the AUC 
(blood glucose level x time) at the end of weight loss phase in any of the studies (Study I ANOVA 
P=0.538; Study II t-test P=0.987; Study III ANOVA P=0.085; Study IV ANOVA P=0.385). 
 
Weight regain phase (Study I, II, and III) 
 
In Study I, the mice in WPI 5 % (P<0.05) and 100 % (P<0.05) groups had lower fasting blood 
glucose levels than the mice in the casein group at the end of the weight regain phase (ANOVA 
P=0.022). In Study II, an increase in the AUC in LF supplementation group was observed as 
compared to casein at the end of the weight regain phase (t-test P=0.029). In Study III, leucine 
supplementation increased the AUC measured in OGTT as compared with α-lac without amino acids 
supplementation (P<0.05).  
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    An important result to emerge from Study I was, when comparing the AUC of the same treatment 
group measured after the weight loss phase and the weight regain phase, there was an increase in the 
AUC in casein group (t-test P=0.003) whereas the value in WPI 100 % group remained unaltered (t-
test P=0.527). 
 
5.5 Energy intake  
 
Weight gain phase (Study IV(i)) 
 
In Study IV, no difference was observed in mean daily energy intake between MFNW, α-lactalbumin 
and casein groups in the weight gain phase (Table 11).  
 
Weight loss phase (Studies I, II, III, and IV(ii)) 
 
The mean daily energy intake, measured during the 100 days pre-feeding period, was used in the 
calculation of 70% energy intake at the beginning of the weight loss phase (in Study III, the pre-
feeding period was 150 days). The energy intake measured from additional age-matched obese mice 
fed ad libitum with casein-based high-fat diet during the weight loss phase from day 100 to day 150 
(in Study III, the value was measured from day 150 to day 200) did not differ from the values 
observed from the pre-feeding period (Study I: t-test P=0.236; Study II: t-test P=0.172; Study III: t-
test P=0.744; Study IV: t-test P=0.063) in any of the studies. There was no difference in daily energy 
intake among the groups during the weight loss phase in Studies I, II, and IV. In Study III, no 
differences were observed between the casein, α-lac+Ca, and AA+Ca groups in daily energy intake 
during the weight loss phase (Table 11). Neither Asp and Trp nor Leu supplementation significantly 
influenced the effects of α-lac on daily energy intake during the weight loss phase (Table 11). 
 
Weight regain phase (Studies I, II, and III) 
 
No difference was observed among the groups in daily energy intake in Studies I or II during the 
weight regain phase. In Study III, when compared to the casein group, no significant differences were 
detected either in the α-lac+Ca group or in the AA+Ca group in daily energy intake during the weight 
regain (Table 11). Neither Asp and Trp nor Leu supplementation significantly influenced the effects 
of α-lac on daily energy intake during the weight regain phase (Table 11). 
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5.6 Apparent fat absorption 
 
In Studies I, II, and III, the mice were housed individually in metabolic cages for 24 h at the end of 
the weight loss and the weight regain phases. The feceal fat content was analyzed and the apparent fat 
absorption was calculated based on the fat intake and excretion data. There was no significant 
difference in the apparent fat absorption between the groups in Studies I or II (Table 11). In Study III, 
the apparent fat absorption was significantly decreased in AA+Ca group compared to both α-lac+Ca 
and casein groups at the end of the weight loss phase (Table 11). A similar statistically non-significant 
difference was also observed at the end of the weight regain phase (Table 11).  
 
5.7 Serum LPS activity 
 
In Study I, serum levels of LPS, a marker of metabolic endotoxemia and low-grade inflammation, 
were analyzed after the weight loss phase. No difference was found among the groups in serum LPS 
concentration (casein: 47.8± 5.4 pg/ml, WPI 5 %: 41.0±2.7 pg/ml, WPI 50 %: 56.5±8.3 pg/ml, WPI 
100 %: 36.0±2.2 pg/ml, ANOVA P=0.07). There was also no difference between the age-matched 
obese mice (casein diet ad libitum feeding) and lean mice (normal rodent chow diet ad libitum feeding) 
(obese controls: 45.3±4.6 pg/ml vs. lean controls: 47.4±8.8 pg/ml, t-test P=0.82). 
 
5.8 Liver histology 
 
In Studies I and II, prominent steatosis was present in the obese mice fed ad libitum. The liver 
histology showed variable degrees of fat accumulation ranging from focal midzonal and perivenular 
vesicle clusters to diffuse macrovesicular fatty changes. Minimal foci of inflammatory cells were 
noted in some samples from the obese mice, but fibrosis was absent in all samples. After the weight 
regain phase, the samples of WPI 100 % group and LF group exhibited less steatosis and improved 
tissue morphology. It is important that the samples of WPI 100 % group showed a complete absence 
of steatosis and displayed histology similar to the lean controls, i.e. the mice which were age-matched 
and had been constantly fed with a normal chow diet. 
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Table 11 Energy intake and apparent fat absorption in different groups during weight gain, weight loss and weight regaina. 
 
      Daily energy intake (kcal/mouse/day) 
 
Apparent fat absorption (%) 
      Weight gain Weight loss Weight regain   Weight loss Weight regain 
 
Study I   
 
Casein control   
 
10.18±0.10 
 
14.88±0.83   
 
93.81±2.06 
 
92.47±1.48 
    WPI 5%   10.06±0.09 18.58±4.14   90.86±1.94 93.42±2.26 
    WPI 50%   9.98±0.01 15.74±0.85   89.65±1.72 95.02±1.72 
    WPI 100%   10.33±0.11 17.10±1.36   90.26±3.36 94.64±0.37 
    ANOVA P   0.10  0.69    0.61 0.71 
         
Study II   Casein control   10.15±0.12 14.70±0.59   92.33±1.98 92.93±1.36 
    Lactoferrin supplementation   10.15±0.02 17.99±1.88   94.17±0.69 95.63±0.75 
    t-test P   0.98  0.24    0.45 0.10  
         
Study III   Casein control   11.16±0.03 16.50±2.70   92.42±1.70 94.94±1.27 
    α-Lac + Ca   11.03±0.03 20.15±0.28   92.07±1.05 94.71±0.83 
    AA + Ca   11.36±0.13 24.03±2.41   81.61±3.42*,## 90.95±1.35 
    α-Lac (2xAsp and Trp) + Ca   11.18±0.04 14.99±0.35   92.32±2.00¤¤ 91.89±1.87 
    α-Lac (2xLeu) + Ca   10.93±0.15¤ 14.41±1.26   91.23±2.09¤¤ 91.48±2.51 
    ANOVA P   0.06 0.045   0.0055 0.3397 
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      Daily energy intake (kcal/mouse/day) 
 
Apparent fat absorption (%) 
      Weight gain Weight loss Weight regain   Weight loss Weight regain 
 
Study IV 
 
(i) 
 
Casein control 
 
13.25±0.52           
    MFNW 13.66±0.96           
    α-Lactalbumin 13.84±0.46           
    ANOVA P 0.83            
         
  (ii) Casein control   10.20±0.00         
    ER MFNW   10.18±0.03         
    ER α-Lactalbumin   10.17±0.03         
    ANOVA P   0.69          
 
 
a Data is presented as mean ± SEM. The asterisk (*) denotes the significant difference in comparison with the casein control group (*P<0.05). #Denotes the significant 
difference in comparison with the α-Lac + Ca group (##P<0.01). ¤Denotes the significant difference in comparison with the AA + Ca group (¤P<0.05, ¤¤P<0.01).
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5.9 Adipose tissue and muscle inflammation 
 
In Study I, in comparison with the age-matched lean control mice, obese mice fed ad libitum with 
casein diet showed increased expression of leptin mRNA (obese 1.00±0.17 vs. lean 0.15±0.06, t-test 
P=0.002), MCP-1 mRNA (obese 1.00±0.19 vs. lean 0.17±0.06, t-test P=0.003), and PAI-1 mRNA 
(obese 1.00±0.22 vs. lean 0.11±0.03, t-test P=0.003) in the adipose tissue. Although ER per se evoked 
a decrease in the expression levels of MCP-1 and leptin mRNA in the adipose tissue in all groups as 
compared to age-matched obese mice fed ad libitum in Study I, no significant difference was 
observed between casein and WPI groups after the weight loss or the weight regain phase. In Study II, 
there was no significant difference in adipocyte MCP-1 mRNA expression between casein and LF 
groups after the weight loss phase, whereas this difference did achieve statistical significance after the 
weight regain phase (t-test P=0.032). 
 
5.10 Hepatic S6 ribosomal protein, AMPK, SIRT1 and SIRT3 expressions 
 
In both Studies I and II, the phosphorylation of S6 ribosomal protein in the liver was markedly 
reduced in WPI (Fig. 7A) and LF (Fig. 7B) groups as compared with the casein group after weight 
loss, whereas these differences did not reach statistical significance after the weight regain phase 
(Study I ANOVA P=0.966; Study II t-test P=0.368). WPI at 50 %, 100 % concentration (Fig. 7C) and 
LF (Fig. 7D) significantly enhanced the hepatic SIRT3 expression at the protein level at the end of the 
weight loss phase. However, these differences were attenuated after the weight regain phase (Study I 
ANOVA P=0.493; Study II t-test P=0.430). In Study I, there were no differences between the casein 
and WPI groups in the phosphorylation level of AMPK or SIRT1 expression after the weight loss 
(AMPK ANOVA P=0.280; SIRT1 ANOVA P=0.321) or the weight regain phase (AMPK ANOVA 
P=0.150; SIRT1 ANOVA P=0.464). 
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Fig. 7 Hepatic S6 ribosomal protein phosphorylation and SIRT3 expression in the liver of C57Bl/6J mice 
after energy restriction in Studies I and II. Data are presented as mean ± SEM. The asterisk (*) denotes 
the significant difference in comparison with casein control group (*P<0.05, **P<0.01)
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6 Discussion 
 
6.1 Methodological aspects 
 
Animal Model 
 
All studies were conducted in the C57Bl/6J mouse strain, which is a well-established model of diet-
induced obesity (Surwit et al., 1988; Collins et al., 2004; Koza et al., 2006; Kanasaki & Koya, 2011). 
This mouse strain is often used as a healthy control animal and as the basis for generating genetically 
modified animal models (Rivera & Tessarollo, 2008), since these mice remain lean and 
physiologically normal when they are fed with a standard rodent diet. After being fed a high-fat diet, 
this mouse strain develops obesity and displays the consequences of obesity i.e. insulin resistance, 
hyperinsulinemia, hypertension, and fatty liver (Collins et al., 2004). Furthermore, the C57Bl/6J 
mouse strain has shown the capacity to develop obesity and its consequences in a relatively short time 
as compared with humans. An increase in body weight was observed after 2 weeks’ high-fat feeding 
and hyperglycemia developed after 4 weeks’ high-fat feeding (Collins et al., 2004; Wang & Liao, 
2012). After 16-20 weeks of high fat feeding, the mice had gained 20-30 % more body weight than 
normally fed mice. These results demonstrate that this mouse strain can serve as a better human-like 
model of obesity and metabolic syndrome than the other widely used obese mouse models, such as 
leptin-deficient ob/ob or leptin-resistant db/db mice.  
 
Diet modification 
 
In all of the studies, the mice were fed with a high-fat diet with constant energy ratio of carbohydrate 
(21 %), protein (18 %) and fat (61 %). The protein sources of the diets in all studies were modified by 
replacing casein with the protein of interest. This approach helps to identify the distinctive effects of 
proteins and allows a direct comparison of the potential of different whey proteins to modify diet-
induced obesity in the experimental mice model. Energy restriction, which was used in all of the 
studies, has been shown to exert beneficial effects on health and to safely induce weight loss in animal 
models (for review see Speakman and Mitchell, 2011).  
    The novel WPI examined in Study I mainly contains lactoperoxidase (about 50 %) and lactoferrin 
(about 15 %), which is different from the normal WPI (lactoperoxidase 0.5 %; lactoferrin 1 %) 
(Krissansen, 2007). It is also rich in immunoglobulins and growth factors. The normal WPI has a high 
BCAA content; the major differences on the amino acids profile between the novel WPI and casein 
are the levels of cysteine, glutamic acid, methionine and proline. The effects of novel WPI observed 
in Study I were further investigated by replacing 15 % of the casein by lactoferrin in the high-fat diet 
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used in Study II. Compared with the normal whey protein which is obtained as a by-product of cheese 
making, the MFNW protein in Study IV is manufactured by a microfiltration technique using a 
polymeric membrane. The MFNW protein is rich in β-lactoglobulin (about 65 %), α-lactalbumin 
(about 24 %) and free of CMP. Based on the amino acid profile, MFNW contains a higher level of 
two BCAAs, leucine and isoleucine, than casein. In comparison with casein, the most enriched amino 
acids in MFNW are cystine and tryptophan.  
    In Study III, the amount of calcium in the diets was modified from 0.79 % to 1.8 %. Since α-
lactalbumin has shown its prominent anti-obese effects in the same mouse strain under high-calcium 
feeding (Pilvi et al., 2009), the effects of α-lactalbumin and an amino acid mixture with an identical 
amino acid profile as in high-calcium diets were evaluated in Study III. In milk, as compared with 
whey proteins, calcium is mainly integrated with casein. However, some whey-derived peptides are 
also known to bind calcium (Vegarud et al., 2000). Therefore, calcium might interact with whey 
protein-derived peptides during digestion, and this may affect the metabolism of both calcium and 
whey proteins.  
 
6.2 Effects of whey proteins on body weight and body fat content 
 
In previous studies, the intake of whey proteins with high calcium supplementation has conferred 
beneficial effects on body weight and fat content in diet-induced obese animal model under high-fat 
feeding (Pilvi et al., 2007; Pilvi et al., 2008; Pilvi et al., 2009). The current results of Studies I, II, and 
IV indicate that without calcium supplementation, whey proteins themselves, including novel WPI, α-
lactalbumin and LF, exert beneficial effects on body weight and fat content in the same model under 
high-fat feeding. The effects of novel WPI in the present study were displayed in a dose-dependent 
manner. The functional component of novel WPI was further studied in Study II by examining the 
effects of LF alone with the same LF concentration (15 %) in novel WPI. It was noted that LF 
supplementation and novel WPI had comparable effects on body weight and fat content, which 
evidences that the effects of novel WPI are largely due to its LF component. In Study IV, the 
observed effects of MFNW on body weight and fat content were about 1/3 of that obtained with α-
lactalbumin. In addition, α-lactalbumin accounted for 24 % of MFNW.  Thus the present results 
suggest that the beneficial effects of MFNW are largely due to its α-lactalbumin content.  
    LF has been reported to exert a modulatory effect on lipid metabolism. Previous studies had 
revealed that the plasma LF level was inversely related to hyperglycemia and positively to insulin 
sensitivity in subjects with insulin resistance (Moreno-Navarrete et al., 2008; Moreno-Navarrete et al., 
2009).  Ono et al. (2010) noted that the enteric-coated LF could decrease visceral fat accumulation in 
obese patients possibly by binding and inactivating LPS and LRP1 to block incorporation of lipid in 
the visceral fat. Thus, these mechanisms may partly explain the effects of novel WPI and LF on body 
weight and fat content found in the present studies. 
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    Whey proteins have been shown to inhibit food intake in humans by increasing feelings of satiety 
(see review Luhovyy et al., 2007). However, the present studies did not detect any differences in 
energy intakes in Studies I, II and IV. The optimal amino acid composition of whey proteins has been 
proposed to account for their potential health effects, especially the high amount of BCAAs, which 
play important roles as both energy substrates and in muscle protein synthesis (Zemel, 2005; Zemel & 
Miller, 2004; Layman & Walker, 2006; Halford et al., 2007). It was found in the present studies that 
there was a higher amount of two BCAAs, leucine and isoleucine, in α-lactalbumin and in the MFNW 
than in casein. Interestingly, although MFNW contains a higher amount of BCAAs than α-
lactalbumin, α-lactalbumin achieved better anti-obesity effects than MFNW. Furthermore, the 
amounts of BCAAs in novel WPI and isoleucine in LF were even less than in casein, but both WPI 
and LF displayed prominent anti-obesity effects in the present studies. Therefore, there are other non-
BCAAs factors which mediate these beneficial metabolic effects of whey proteins.   
    In comparison with casein, the most enriched amino acids in novel WPI were cystine and arginine, 
whereas in LF they were cystine and glycine, in α-lactalbumin cystine and aspartic acid, and in 
MFNW cystine and tryptophan. If one considers these amino acids, arginine has been shown to reduce 
adiposity in both genetically (Fu et al., 2005; Wu et al., 2007c) and diet-induced obese rats (Jobgen et 
al., 2009), pigs (He et al., 2009) and in obese human subjects with type 2 diabetes (Lucotti et al., 
2006). There are recent studies indicating that arginine can stimulate mitochondrial biogenesis and 
brown adipose tissue development possibly by enhancing the synthesis of cell-signaling molecules 
and triggering the expression of genes which promote whole-body oxidation of energy substrates 
(McKnight et al., 2010), which may partly explain the effects of the novel WPI on body weight and 
fat content noted in Study I. Typtophan, the precursor of the neurotransmitter serotonin, has been 
suggested to be involved in the regulation of appetite through the anorexic effects of serotonin in the 
central nervous system (Halford et al., 2007). Cysteine has been reported to be a precursor for the 
most abundant intracellular antioxidant glutathione (Wu et al., 2004). It is of great interest that cystine 
is the most enriched amino acid in all whey proteins tested here as compared with casein. Therefore, 
the role of amino acid composition in the anti-obesity effects of whey proteins remains to be clarified.   
    Alpha-lactalbumin has been reported to exert beneficial effects on obesity and obesity related 
metabolic disorders (Nieuwenhuizen et al., 2008; Pilvi et al., 2009; Hursel et al., 2010). There is a 
report that, when combined with calcium supplementation, α-lactalbumin is the most promising whey 
protein fraction (i.e. out of normal WPI, α-lactalbumin, β-lactoglobulin, and LF) for improving the 
outcome of weight loss and weight regain during high-fat feeding (Pilvi et al., 2009). The present 
studies investigated the effects of α-lactalbumin and an amino acid mixture with an equivalent amino 
acid profile on diet-induced obesity in the same mouse model and with calcium supplementation in 
order to explore the anti-obesity effects of α-lactalbumin on a molecular basis. It was found that the 
effects of α-lactalbumin could be reproduced by providing an amino acid mixture with an identical 
amino acid profile during ER, which indicates that the anti-obesity effects of α-lactalbumin were 
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mainly being mediated by its amino acid composition rather than by any peptides formed during 
digestion.  
    Dietary calcium intake has been shown to have beneficial effects on body weight by increasing fat 
excretion (Christensen et al., 2009) as well as promoting 1,25-dihydroxy-vitamin D3-mediated 
alterations in adipocyte metabolism (Zemel, 2000; Shi et al., 2001a; Shi et al., 2002; Zemel & Miller, 
2004). Therefore, this may explain the only difference in fat excretion found with calcium 
supplementation in Study III, which in turn at least partly accounts for the observed effects on body 
weight and fat content detected in Study III. There did not appear to be any difference in apparent fat 
absorption in Studies I and II, which indicates that an intake of whey proteins without calcium 
supplementation does not interfere with the fat digestibility during high-fat feeding. In a previous 
study, Pilvi et al. (2007) observed that whey proteins increased the fat excretion as compared with 
casein during high-calcium high-fat feeding, which suggests that milk proteins may affect the calcium 
binding fatty acids properties. Interestingly, in Study III, it was also found that the increased fat 
excretion in the amino acid mixture with an identical amino acid profile of α-lactalbumin group as 
compared with α-lactalbumin group. However, it is unclear whether the changes in calcium binding 
properties between α-lactalbumin and amino acids mixture actually contribute to the differences in fat 
excretion. 
    Although a large proportion of the whey proteins, and their peptides which are bioavailable after 
hydrolysis in the intestine, are ultimately degraded into amino acids, which are taken up into the blood 
circulation from the small intestine, it does seem that there are certain whey proteins and their derived 
peptides which are resistant to hydrolysis. Whey-derived peptides have shown several bioactivities 
including opioid agonist (α-lactorphin), opioid antagonists (lactoferroxins), ACE-inhibitory 
(lactokinins), and antimicrobial (lactoferricin) (Jones et al., 1994; Teschemacher et al., 1997; 
FitzGerald & Meisel, 1999; Meisel, 2005; Korhonen & Pihlanto, 2006; Yalcin, 2006; Hartmann & 
Meisel, 2007). Interestingly, a novel hypocholesterolemic peptide derived from β-lactoglobulin 
clearly affected serum cholesterol level in rats in comparison with β-sitosterol (Nagaoka et al., 2001). 
It is possible that certain whey protein-derived peptides may also play an important role in mediating 
the anti-obesity effects of whey proteins (Torres-Fuentes et al., 2014). The potential whey-derived 
peptides with anti-obese effects still need to be studied in future. 
 
6.3 Effects of whey proteins on fatty liver formation, glucose homeostasis and adipose 
tissue 
 
In Studies I and II, the obesity-induced fatty liver formation was based on a previously published and 
validated histological scoring system (Kleiner et al., 2005; Tiniakos et al., 2010). Although this 
system was intended to detect NAFLD in clinical trials, one could propose that it is also suitable for 
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screening fatty liver formation in animal models. It was noted that both novel WPI and LF 
ameliorated the ectopic fat accumulation after the weight loss and inhibited fatty liver formation after 
the weight regain, especially WPI which in Study I completely blocked fatty liver formation after the 
weight regain. Insulin resistance is clearly associated with ectopic fat accumulation in muscle and 
liver. The decreased body fat content can improve insulin sensitivity, which is consistent with the 
lower fasting blood glucose levels found in WPI and LF groups after the weight regain and the 
improved insulin sensitivity as reflected in blood glucose-time-area under curves from OGTT after the 
weight loss and the regain phases in the present studies. In addition, it was observed that the improved 
insulin sensitivity obtained with LF was associated with a reduction in skeletal muscle leptin mRNA 
expression pointing to an amelioration of obesity-induced ectopic fat accumulation within muscle. It 
is of great interest that there was more severe liver damage after the weight regain in the casein 
control group as compared with the age-matched group which was consuming casein diet during the 
whole follow-up period ad libitum in Study II. This severe liver damage is likely to be mediated, at 
least partly, via weight gain and fat accumulation i.e. the rebound effects on body weight and fat 
content in the casein group after the weight regain phase.  
    Chronic adipose tissue inflammation has been postulated to play a key role in the development of 
obesity-related insulin resistance (Weisberg et al., 2003; Xu et al., 2003; Tilg & Moschen, 2006). The 
release of cytokines is known to trigger the recruitment and activation of immune cells to sites of 
inflammation. LF has been reported to modulate the inflammatory process mainly by preventing the 
release of cytokines (Legrand et al., 2005), which explains the findings in Study II that LF 
ameliorated obesity-induced low grade inflammation measured as MCP-1 mRNA expression in the 
visceral fat. It has been postulated that high-fat feeding induced low grade inflammation is at least 
partly due to the increased intestinal permeability leading to endotoxemia (Cani et al., 2007). Unlike 
other whey protein fractions, LF is partially resistant against proteolytic degradation, and thus it is 
retained at least to some degree as undigested molecule or as lactoferricin-containing peptides in the 
gastrointestinal tract (Kuwata et al., 2001; Tomita et al., 2009). Previous research has found evidence 
for the down-regulation of cytokines by LF to be partly related to the LPS-binding properties of LF 
through its lactoferricin domain (Appelmelk et al., 1994; Elass-Rochard et al., 1995; Brandenburg et 
al., 2001). However, the present studies were unable to detect any difference in the concentration of 
serum LPS between obese and lean control groups. Thus, it is not clear whether the anti-inflammatory 
effects of LF found in the present studies were linked to its LPS binding properties and this will need 
to be evaluated in the future. 
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6.4 Effects of whey proteins and energy restriction on nutrient sensing signaling 
pathways 
 
The nutrient sensor links regulating energy intake and metabolism are complex. AMPK is known to 
be a highly conserved ultrasensitive energy sensor and it participates in the regulation of energy-
generating and energy-consuming pathways, i.e. it integrates nutritional and hormonal signals in both 
peripheral tissues and in the hypothalamus (Kahn et al., 2005), AMPK has been proposed to mediate 
the effects of adipokines to regulate food intake, body weight and lipid, glucose metabolism (Kahn et 
al., 2005). The activation of AMPK in the peripheral tissues reduces the risk of obesity and insulin 
resistance by stimulating fatty acid oxidation and enhancing glucose transport and metabolism (Kahn 
et al., 2005). The beneficial effects of AMPK activation are largely mediated via the inhibition of the 
mTOR-S6 kinase (S6K1) pathway, which is chronically activated by nutrient excess (Kahn et al., 
2005; Korsheninnikova et al., 2006). Previous research has revealed that high-fat feeding can increase 
S6 phosphorylation in the liver (Korsheninnikova et al., 2006), whereas S6K1-deficient mice were 
protected against the obesity attributable to enhanced β-oxidation (Um et al., 2004). In agreement with 
the above findings, the present studies found that weight loss under ER in both novel WPI and LF fed 
mice was associated with decreased hepatic S6 ribosomal protein phosphorylation. Sirtuins, a highly 
conserved family of NAD
+
-dependent enzymes regulating life span in lower organisms, have been 
claimed to act as metabolic sensors and mediators of the cellular effects of caloric restriction (Finkel 
et al., 2009; Haigis & Sinclair, 2010).  SIRT3, which is a member of this family, has been reported to 
regulate mitochondrial function, thermogenesis and mitochondrial fatty acid oxidation. SIRT3 is the 
only sirtuin for which there is a reported association with human lifespan (Finkel et al., 2009; Haigis 
& Sinclair, 2010). Previous research has demonstrated that mice fed with high-fat diet exhibited a 
reduced level of SIRT3 activity in the liver, decreased hepatic NAD
+
 levels and increased 
mitochondrial function (Kendrick et al., 2011). In good agreement with these findings, it was found 
that there was increased hepatic SIRT3 expression in both novel WPI and LF fed mice after ER. 
These findings indicate that the metabolic effects of novel WPI and LF might be partly mediated via 
inhibition of the mTOR nutrient sensing pathway and activation of SIRT3 in the liver. However, this 
is speculation since the enzyme activity of SIRT3 was not determined. Therefore, the cellular 
mechanism mediating the dietary alteration effects on the above mentioned nutrient sensors will need 
to be clarified in the future. 
 
6.5 Clinical relevance 
 
The aim of obesity treatment is to prevent and treat other obesity associated diseases such as type 2 
diabetes, cardiovascular diseases, sleep apnoea and osteoarthritis by achieving a permanent at least 5 % 
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reduction of body weight (Tsigos et al., 2008). In the present studies, whey proteins inhibited weight 
gain under ad libitum energy intake, as well as enhancing the weight loss due to 30 % decreased 
energy intake below ad libitum intake and the whey proteins also prevented weight regain with 
subsequent ad libitum energy intake. Although the results of an animal experiment cannot be directly 
applicable to human beings, the present study confirms the anti-obesity effects of different whey 
proteins and indicates that increasing the amount of whey protein content in diets could be beneficial 
during both weight loss and in subsequent weight maintenance.   
    The current treatment of NAFLD is primarily aimed to slow the progression of NAFLD, and to 
prevent liver-related illness and death (Adams et al., 2005; Bjornsson & Angulo, 2007). Life style 
management has been suggested as the first step towards improving NAFLD (Adams et al., 2005; 
Bjornsson & Angulo, 2007). In the present studies, whey proteins ameliorated fat accumulation in 
liver in conditions of energy restriction and prevented fatty liver formation after weight regain. 
Although these results cannot be directly extrapolated to humans, it is tempting to recommend that 
whey proteins supplementation could become a part of the life style management in the treatment of 
NAFLD. 
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7 Conclusions 
 
The aim of the present study was to investigate the potential of different whey proteins and their 
mechanisms of actions, including whey protein isolate (WPI), alpha-lactalbumin (α-lac), lactoferrin 
(LF) and microfiltered native whey (MFNW), in the prevention and treatment of diet-induced obesity 
and its consequences in C57Bl/6J mice. The main findings and conclusions of the present study were 
as follows: 
 
1. WPI dose-dependently accelerated weight and fat loss and prevented weight and fat regain 
during high-fat-feeding in C57Bl/6J mice. WPI ameliorated obesity induced fatty liver 
formation and improved glucose tolerance without influencing energy intake, apparent fat 
digestibility, or adipose tissue inflammation. These findings indicate that the effects of WPI 
are mediated, at least partly, via the inhibition of the mTOR nutrient sensing pathway and the 
activation of SIRT3 in liver.  
 
2. LF enhanced weight and fat loss and inhibited weight and fat regain in C57Bl/6J mice fed a 
high fat diet. LF exerted beneficial effects on glucose tolerance, adipose tissue inflammation 
and it ameliorated the obesity induced fatty liver formation without interfering with energy 
intake or apparent fat digestibility. It is suggested that the effects of LF are mediated, at least 
partly, via the inhibition of the mTOR nutrient sensing pathway and the activation of SIRT3 in 
liver. 
 
3. The anti-obesity effects of α-lac under energy restriction could be reproduced by feeding an 
amino acid mixture with an equivalent amino acid profile. The findings indicate the anti-
obesity effects of α-lac are mainly attributable to its amino acid composition. 
 
4. The MFNW produced by polymeric membranes, was able to prevent weight gain and fat 
accumulation without interfering with glucose homeostasis or energy intake in high-fat-fed 
C57Bl/6J mice. This may be a possible method to generate whey proteins with high bioactive 
value in a large scale. The findings also indicate these effects of MFNW are largely due to its 
abundant α-lac content.  
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